<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Biomedicines</journal-id>
<journal-id journal-id-type="iso-abbrev">Biomedicines</journal-id>
<journal-id journal-id-type="publisher-id">biomedicines</journal-id>
<journal-title-group>
<journal-title>Biomedicines</journal-title>
</journal-title-group>
<issn pub-type="epub">2227-9059</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32823757</article-id>
<article-id pub-id-type="pmc">7460013</article-id>
<article-id pub-id-type="doi">10.3390/biomedicines8080286</article-id>
<article-id pub-id-type="publisher-id">biomedicines-08-00286</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Dietary Flavonoids in p53—Mediated Immune Dysfunctions Linking to Cancer Prevention</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7028-290X</contrib-id>
<name>
<surname>Siddiqui</surname>
<given-names>Shoib Sarwar</given-names>
</name>
<xref ref-type="aff" rid="af1-biomedicines-08-00286">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rahman</surname>
<given-names>Sofia</given-names>
</name>
<xref ref-type="aff" rid="af2-biomedicines-08-00286">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3435-0052</contrib-id>
<name>
<surname>Rupasinghe</surname>
<given-names>H.P. Vasantha</given-names>
</name>
<xref ref-type="aff" rid="af3-biomedicines-08-00286">3</xref>
<xref ref-type="aff" rid="af4-biomedicines-08-00286">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2742-6277</contrib-id>
<name>
<surname>Vazhappilly</surname>
<given-names>Cijo George</given-names>
</name>
<xref ref-type="aff" rid="af1-biomedicines-08-00286">1</xref>
<xref ref-type="corresp" rid="c1-biomedicines-08-00286">*</xref>
</contrib>
</contrib-group>
<aff id="af1-biomedicines-08-00286"><label>1</label>Department of Biotechnology, American University of Ras Al Khaimah, Ras Al Khaimah PO Box 10021, UAE; <email>shoib.siddiqui@aurak.ac.ae</email></aff>
<aff id="af2-biomedicines-08-00286"><label>2</label>School of Natural Sciences and Mathematics, The University of Texas at Dallas, Richardson, TX 75080, USA; <email>sofiarahman0@gmail.com</email></aff>
<aff id="af3-biomedicines-08-00286"><label>3</label>Department of Plant, Food, and Environmental Sciences, Faculty of Agriculture, Dalhousie University, Truro, NS B2N 5E3, Canada; <email>vrupasinghe@dal.ca</email></aff>
<aff id="af4-biomedicines-08-00286"><label>4</label>Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada</aff>
<author-notes>
<corresp id="c1-biomedicines-08-00286"><label>*</label>Correspondence: <email>cijo.vazhappilly@aurak.ac.ae</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>8</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>8</month>
<year>2020</year>
</pub-date>
<volume>8</volume>
<issue>8</issue>
<elocation-id>286</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>6</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>8</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The p53 protein plays a central role in mediating immune functioning and determines the fate of the cells. Its role as a tumor suppressor, and in transcriptional regulation and cytokine activity under stress conditions, is well defined. The wild type (WT) p53 functions as a guardian for the genome, while the mutant p53 has oncogenic roles. One of the ways that p53 combats carcinogenesis is by reducing inflammation. WT p53 functions as an anti-inflammatory molecule via cross-talk activity with multiple immunological pathways, such as the major histocompatibility complex I (MHCI) associated pathway, toll-like receptors (TLRs), and immune checkpoints. Due to the multifarious roles of p53 in cancer, it is a potent target for cancer immunotherapy. Plant flavonoids have been gaining recognition over the last two decades to use as a potential therapeutic regimen in ameliorating diseases. Recent studies have shown the ability of flavonoids to suppress chronic inflammation, specifically by modulating p53 responses. Further, the anti-oxidant Keap1/Nrf2/ARE pathway could play a crucial role in mitigating oxidative stress, leading to a reduction of chronic inflammation linked to the prevention of cancer. This review aims to discuss the pharmacological properties of plant flavonoids in response to various oxidative stresses and immune dysfunctions and analyzes the cross-talk between flavonoid-rich dietary intake for potential disease prevention.</p>
</abstract>
<kwd-group>
<kwd>flavonoids</kwd>
<kwd>inflammation</kwd>
<kwd>p53</kwd>
<kwd>cancer prevention</kwd>
<kwd>Nrf2 pathway</kwd>
<kwd>anti-oxidant</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-biomedicines-08-00286" sec-type="intro">
<title>1. Introduction</title>
<p>One of the hallmarks of cancer is genome instability due to DNA damage [<xref ref-type="bibr" rid="B1-biomedicines-08-00286">1</xref>]. There are several genes implicated in modulating the pathways related to DNA damage and repair response [<xref ref-type="bibr" rid="B2-biomedicines-08-00286">2</xref>]. An impetus to this field of research was provided by the discovery of the first tumor suppressor gene p53 in SV-transformed cells in 1979 [<xref ref-type="bibr" rid="B3-biomedicines-08-00286">3</xref>]. However, the history of p53 is rather interesting. Initially, it was observed that p53 could accumulate in cancer cells and a knockdown of the gene led to the inhibition of cell proliferation. Thus, scientists presumed that it was an “oncogene.” The identification of new oncogenes was fascinating [<xref ref-type="bibr" rid="B4-biomedicines-08-00286">4</xref>]. However, over the last four decades, p53 has evolved from the realization of a tumor suppressor protein to transcription factor, a regulator of metabolic pathways, a regulator of cytokine activity, and a drug target for cancer therapy [<xref ref-type="bibr" rid="B4-biomedicines-08-00286">4</xref>]. Due to its role in the DNA damage and repair process, the tumor suppressor <italic>p53</italic> gene is often referred to as the “guardian of the genome” [<xref ref-type="bibr" rid="B5-biomedicines-08-00286">5</xref>].</p>
<p>Several reports and observations showed the role of p53 as an oncogene. However, it was observed in many tumor models that the mouse <italic>Trp53</italic> is inactivated by the retroviral insertions pointing towards its potential role as a tumor suppressor gene [<xref ref-type="bibr" rid="B6-biomedicines-08-00286">6</xref>,<xref ref-type="bibr" rid="B7-biomedicines-08-00286">7</xref>]. This p53 conundrum took a turn when the cloned wild type (WT) p53 sequence was compared with the tumor expressing p53 and it was observed that the tumor-promoting activity of p53 is due to its mutant form found in cancer cells [<xref ref-type="bibr" rid="B4-biomedicines-08-00286">4</xref>]. In an elegant study on colorectal cancer, it was shown that more than 50% of tumors had a loss of heterozygosity (LOH) at the p53 locus, thus providing further evidence of its role as a tumor suppressor [<xref ref-type="bibr" rid="B8-biomedicines-08-00286">8</xref>]. Further experiments strengthen the notion that the wild type p53 can suppress oncogenic transformation [<xref ref-type="bibr" rid="B9-biomedicines-08-00286">9</xref>]. The analysis of p53 knockout mice was interesting. The mice were developmentally normal but developed primary lymphomas and sarcomas at around 6 to 9 months of age [<xref ref-type="bibr" rid="B10-biomedicines-08-00286">10</xref>]. In human patients, the early clues came in the 1960s from the group of people who were highly prone to develop cancer due to a rare autosomal mutation. This syndrome was called Li-Fraumeni syndrome (LFS) [<xref ref-type="bibr" rid="B11-biomedicines-08-00286">11</xref>,<xref ref-type="bibr" rid="B12-biomedicines-08-00286">12</xref>]. Later, the specific mutation was identified as a germline mutation in <italic>TP53</italic> [<xref ref-type="bibr" rid="B13-biomedicines-08-00286">13</xref>,<xref ref-type="bibr" rid="B14-biomedicines-08-00286">14</xref>].</p>
<sec id="sec1dot1-biomedicines-08-00286">
<title>1.1. p53 as a Transcription Factor</title>
<p>p53 acts as a transcription regulator under stress conditions. After the acceptance of p53 as a tumor suppressor, several studies were published in the early 1990s leading to the role of p53 as a transcription factor [<xref ref-type="bibr" rid="B15-biomedicines-08-00286">15</xref>,<xref ref-type="bibr" rid="B16-biomedicines-08-00286">16</xref>,<xref ref-type="bibr" rid="B17-biomedicines-08-00286">17</xref>]. Wild type p53 has been shown to have DNA binding ability, while its mutant counterpart, often found in cancer cells, does not have this ability [<xref ref-type="bibr" rid="B15-biomedicines-08-00286">15</xref>,<xref ref-type="bibr" rid="B16-biomedicines-08-00286">16</xref>,<xref ref-type="bibr" rid="B17-biomedicines-08-00286">17</xref>]. Moreover, the effect of p53 as a transcription activator is direct, but the effect as a repressor is indirect [<xref ref-type="bibr" rid="B15-biomedicines-08-00286">15</xref>,<xref ref-type="bibr" rid="B16-biomedicines-08-00286">16</xref>,<xref ref-type="bibr" rid="B17-biomedicines-08-00286">17</xref>]. Further, p53 regulates the transcription of genes that are important for apoptosis, cell cycle, and DNA repair machinery [<xref ref-type="bibr" rid="B4-biomedicines-08-00286">4</xref>]. p53 functions as a pioneer transcription factor. The binding of p53 to nucleosomal DNA takes place through the linker DNAs. p53 also binds to histone protein through the N-terminal 1–93 amino acid region [<xref ref-type="bibr" rid="B18-biomedicines-08-00286">18</xref>]. In a recent study, it was identified that the transcriptional regulation of porcine p53 is very similar to human p53 for a number of target genes, and, thus, it is inferred that pigs can be used to study human diseases [<xref ref-type="bibr" rid="B19-biomedicines-08-00286">19</xref>]. The role of p53 as a transcription factor is also shown in several disease models. Human dihydroorotate dehydrogenase (DHODH) is an enzyme involved in de novo synthesis of pyrimidines. Tetrahydroindazoles (HZ) have been identified as potent inhibitors of DHODH. HZ analogs have been shown as promising agents against cancer progression. The cell-based reporter showed that HZ functions by activating the p53-dependent transcription activity [<xref ref-type="bibr" rid="B20-biomedicines-08-00286">20</xref>]. The autosomal dominant polycystic kidney disease (ADPKD) is mainly caused by the mutations in the PKD1 or PKD2 genes. The recent studies showed that PKD1 gene expression is controlled by the overlapping but opposing transcriptional activity of Myc and p53 [<xref ref-type="bibr" rid="B21-biomedicines-08-00286">21</xref>]. Esophageal Cancer-Related Gene 2 (ECRG2) is a tumor suppressor whose activity is highly regulated by the transcriptional activity of p53. It was identified for two p53 binding sites within the promoter of ECRG2, and thus its mRNA and protein expression is regulated [<xref ref-type="bibr" rid="B22-biomedicines-08-00286">22</xref>].</p>
</sec>
<sec id="sec1dot2-biomedicines-08-00286">
<title>1.2. p53 as a Regulator of Metabolic Pathways</title>
<p>One of the hallmarks of cancer is the shift to glycolysis as the predominant metabolic pathway for the generation of energy, despite oxidative phosphorylation being an efficient way to produce adenosine triphosphate (ATP). This is referred to as the “Warburg effect.” Due to this, cancer cells utilize a higher amount of glucose compared to normal cells. Both the oncogenes and tumor suppressor genes have been shown to play a pivotal role in the regulation of this phenomenon. p53 is one of the factors that reduce the utilization of glycolysis and enhance the oxidative phosphorylation of cancer cells [<xref ref-type="bibr" rid="B23-biomedicines-08-00286">23</xref>]. Thus, p53 plays a vital role in this metabolic pathway, which is also a hallmark for cancer cells [<xref ref-type="bibr" rid="B1-biomedicines-08-00286">1</xref>]. p53, together with other tumor suppressor genes, carries out the function of immunological homeostasis. Moreover, the transcriptional activity of p53 regulates the expression and signaling of a number of cytokines and some of these cytokines activate p53 expression suggesting a positive feedback loop. In addition, the immune checkpoint regulators, such as program cell death protein 1 (PD1) and program cell death ligand 1 (PDL1), also cross-talk with p53 and thus modulate the overall immune responses [<xref ref-type="bibr" rid="B24-biomedicines-08-00286">24</xref>].</p>
</sec>
<sec id="sec1dot3-biomedicines-08-00286">
<title>1.3. p53 as a Drug Target for Cancer</title>
<p>As discussed previously, more than 50% of all cancer has a p53 mutation [<xref ref-type="bibr" rid="B25-biomedicines-08-00286">25</xref>]. p53 is important for homeostatic signaling in cell proliferation, cell cycle regulation, apoptosis, senescence, and inflammation, and a mutation in this crucial protein leads to malignancy. The most common mutation in p53 is a single amino acid substitution, which leads to the loss of DNA binding function and misfolding of the protein. There has been a thrust to develop drugs that can restore the WT activity in the missense mutant proteins. This restoration of WT activity in mutant p53 is often referred to as a “reactivating mutant” [<xref ref-type="bibr" rid="B26-biomedicines-08-00286">26</xref>]. Although many such drug candidates have been developed, most of them failed during the early developmental phase [<xref ref-type="bibr" rid="B26-biomedicines-08-00286">26</xref>]. The reactivation of p53 is a major pharmacological intervention and has been suggested to have promising effects for cancer therapy. PhiKan083, also known as PK083, has been shown to reactivate p53 mutants under pre-clinical settings. Using virtual screening and validation on different p53 mutants, it was shown that Y220C and Y220S are the targets of PK083 [<xref ref-type="bibr" rid="B27-biomedicines-08-00286">27</xref>]. In another study with virtual screening on natural compounds targeting the Loop1/Sheet 3 (L1/S3) of WT-p53, a drug candidate torilin was identified. Torilin not only improved p53 activity but also enhanced protein expression of p21. This ultimately led to the suppression of HCT116 cancer cell growth [<xref ref-type="bibr" rid="B28-biomedicines-08-00286">28</xref>]. It is noteworthy that around 80% of triple-negative breast cancer (TNBC) patients have a mutation in p53. Therefore, reactivating p53 mutants by drugs can be prolific for clinical intervention. One such drug recently studied for TNBC is 2-sulfonylpyrimidine compound, PK11007. PK11007 targets the apoptotic pathway of cell death in TNBC cell lines [<xref ref-type="bibr" rid="B29-biomedicines-08-00286">29</xref>]. These recent studies highlighted the role of p53 as an attractive drug target for cancer therapy.</p>
</sec>
</sec>
<sec id="sec2-biomedicines-08-00286">
<title>2. p53-Mediated Inflammatory Response and Immune Signaling</title>
<p>The role of inflammation in the promotion of cancer is well defined and is considered as an important hallmark of the disease [<xref ref-type="bibr" rid="B1-biomedicines-08-00286">1</xref>]. Cancer leads to inflammation and in many instances, chronic inflammation leads to cancer [<xref ref-type="bibr" rid="B30-biomedicines-08-00286">30</xref>]. The oxidative stress induced by reactive oxygen and nitrogen species [<xref ref-type="bibr" rid="B31-biomedicines-08-00286">31</xref>] and viral and bacterial infection is associated with cancer risk [<xref ref-type="bibr" rid="B32-biomedicines-08-00286">32</xref>]. How p53 is involved in cancer-related inflammation in the tumor microenvironment is an interesting question. p53 acts as a suppressor of inflammation, but proof came from the p53 knockout mouse, which itself led to chronic inflammation in mice, but not sufficient enough to cause cancer. It was observed that many of the mice died before the progression of the tumor due to chronic inflammation [<xref ref-type="bibr" rid="B10-biomedicines-08-00286">10</xref>,<xref ref-type="bibr" rid="B33-biomedicines-08-00286">33</xref>]. In an experimental autoimmune encephalomyelitis (EAE) model, p53 knockout mice showed severe inflammation in the central nervous system (CNS) [<xref ref-type="bibr" rid="B34-biomedicines-08-00286">34</xref>]. In a collagen-induced arthritis (CIA) model, p53 knock out mice developed more severe arthritis symptoms compared to WT DBA/1 mice [<xref ref-type="bibr" rid="B35-biomedicines-08-00286">35</xref>]. This is further proof for the role of p53 as an anti-inflammatory target. Using an azoxymethane (AOM)-induced colon cancer model in a conditional knockout mouse of p53, it was shown that the loss of p53 in stem cells leads to tumor formation with a combinational effect of DNA damage and chronic inflammation [<xref ref-type="bibr" rid="B36-biomedicines-08-00286">36</xref>].</p>
<p>Further, to identify the functioning of p53 as an anti-inflammatory agent, several studies have been carried out and linked with the transcription factor nuclear factor-κB (NF-κB). p53 suppresses the activity of NF-κB by inhibiting the transcriptional activity of p65 or suppressing the activation of p65 by IκB kinase (IKK) and proteasomal degradation of IκB. It is noteworthy that IκB acts as an inhibitor of NF-κB [<xref ref-type="bibr" rid="B37-biomedicines-08-00286">37</xref>,<xref ref-type="bibr" rid="B38-biomedicines-08-00286">38</xref>]. In the studies pertaining to gastric cancer caused by <italic>Helicobacter Pylori</italic>, it has been shown that the virulence factor cytotoxin-associated gene A (CagA) activates NF-κB and induces inflammation in gastric epithelial cells [<xref ref-type="bibr" rid="B39-biomedicines-08-00286">39</xref>,<xref ref-type="bibr" rid="B40-biomedicines-08-00286">40</xref>,<xref ref-type="bibr" rid="B41-biomedicines-08-00286">41</xref>]. This activation of NF-κB further enhances the expression of activation-induced cytidine deaminase (AICDA), which promotes cancer by incorporating <italic>TP53</italic> mutations [<xref ref-type="bibr" rid="B42-biomedicines-08-00286">42</xref>]. In addition, the inflammatory bowel diseases are characterized by the infiltration of neutrophils that are rich sources of free radical species. These free radicals have been shown to promote cancer progression by incorporating mutations in the <italic>TP53</italic> gene [<xref ref-type="bibr" rid="B39-biomedicines-08-00286">39</xref>,<xref ref-type="bibr" rid="B43-biomedicines-08-00286">43</xref>,<xref ref-type="bibr" rid="B44-biomedicines-08-00286">44</xref>].</p>
<sec id="sec2dot1-biomedicines-08-00286">
<title>2.1. Cross-Talk between p53 and MHCI Pathway</title>
<p>The major histocompatibility complex (MHC), derived the name from its discovery with the research on tissue compatibility upon transplantation. These are an important class of gene complexes that play a pivotal role in recognition of foreign antigens. Being expressed on the cell surface, they interact with T-cell receptors (TCR) and pose an immune response against the endogenous or exogenous antigens [<xref ref-type="bibr" rid="B45-biomedicines-08-00286">45</xref>]. MHCI is expressed on the surface of all nucleated cells (epithelial or fibroblasts) and is involved in showcasing the intracellular proteins on the cell surface in the form of short peptides. The processing and transport of these small peptides is a complex process that involves the interplay of several proteins, including transporter associated with antigen processing 1 (TAP1) and TAP2. It has been shown previously that one of the alleles of MHCI, human leukocyte antigen B7, can be transcriptionally repressed by the tumor suppressor gene p53 [<xref ref-type="bibr" rid="B46-biomedicines-08-00286">46</xref>]. Several other studies pointed out that p53 can promote the processing of peptides inside the cell and modulate the surface expression of MHC1 [<xref ref-type="bibr" rid="B47-biomedicines-08-00286">47</xref>,<xref ref-type="bibr" rid="B48-biomedicines-08-00286">48</xref>]. In addition to these changes, the transcriptional activity of p53 can upregulate the expression of TAP1 (a protein involved in the transport of peptides toMHC1).</p>
<p>Moreover, p53 also upregulates the expression of ERAP1 (endoplasmic reticulum aminopeptidase 1), which leads to enhanced expression of MHCI on the cell surface [<xref ref-type="bibr" rid="B47-biomedicines-08-00286">47</xref>,<xref ref-type="bibr" rid="B48-biomedicines-08-00286">48</xref>]. The cumulative effect of this p53 processing resulted in an enhanced immune response against cancer. Interestingly, the mutant p53 has lost the activity of all these processes, which emphasizes the dysregulated immune function and oncogenic role of mutant p53. On the contrary, it has been observed that the loss of function of important genes in the MHCI processing pathway, such as β2 microglobulin and TAP1, also leads to a reduction in the function of p53, proposing a cross-talk between MHCI and the p53 pathway [<xref ref-type="bibr" rid="B39-biomedicines-08-00286">39</xref>]. In a recent study, it was shown that the lack of p53 in medulloblastoma leads to the loss of MHCI expression and resistance to immune rejection. The mechanistic study showed that this is due to the loss of expression of TAP1 and ERAP1, but tumor necrosis factor factor-alpha (TNF-α) agonists can rescue the expression of these proteins. Moreover, in vivo studies also supported the notion that the p53 null state plays a pivotal role in immune evasion, and TNF can reverse this phenotype [<xref ref-type="bibr" rid="B49-biomedicines-08-00286">49</xref>].</p>
</sec>
<sec id="sec2dot2-biomedicines-08-00286">
<title>2.2. Cross-Talk between p53 and Immune Checkpoints</title>
<p>To mount an immune response, the MHCI showcase the peptide to the surface of the TCR of T cells. Once activated, T cells start to express PD1 that react with PD-L1. This PD1/PDL1 axis is instrumental in maintaining the protective immunity and homeostatic condition. Beside PD1/PDL1, a flurry of other receptor–ligand complexes keep the immune system in check. These receptor–ligand complexes are called immune checkpoints [<xref ref-type="bibr" rid="B50-biomedicines-08-00286">50</xref>]. These immune checkpoints are vital for maintaining the physiological resting state of immune cells (T cells). However, in the case of cancer progression, cancer cells hijack this process and engage T cells for immune evasion. The overexpression of PDL1 ligands on their surface of cancer cells to engage with PD1 of T cells is well recognized. This engagement of PD1 with PDL1 ultimately leads to immunosuppression [<xref ref-type="bibr" rid="B51-biomedicines-08-00286">51</xref>]. Targeting this pathway is considered as a hotspot for cancer immunotherapy. It was identified that miR-34a, which acts as a transcriptional target of p53, is actually a repressor of PDL1. Thus, p53/miR-34a/PDL1 can be a suitable target for cancer immunotherapy [<xref ref-type="bibr" rid="B52-biomedicines-08-00286">52</xref>]. A loss of p53 activity by a mutation in human lung cancer has been shown to upregulate PD-L1 expression. Thus it will be instrumental in predicting the patient pool that may or may not be responsive to checkpoint inhibitors targeting the PD1/PDL1 axis [<xref ref-type="bibr" rid="B53-biomedicines-08-00286">53</xref>].</p>
</sec>
<sec id="sec2dot3-biomedicines-08-00286">
<title>2.3. Cross-Talk between p53 and TLRs</title>
<p>Toll-like receptors (TLRs) are the receptors that detect pathogen-associated molecular patterns (PAMPs), present mostly on the microbial surfaces [<xref ref-type="bibr" rid="B54-biomedicines-08-00286">54</xref>]. Many TLRs were also found on the surface of cancer cells as well. TLR signaling on cancer cells mediates a number of functions that trigger cancer progression. Therefore, TLRs are considered as another attractive target for cancer immunotherapy [<xref ref-type="bibr" rid="B55-biomedicines-08-00286">55</xref>]. It was shown that p53 could act as a transcriptional activator of TLR3 that can trigger agonist-induced apoptosis in cancer cells [<xref ref-type="bibr" rid="B56-biomedicines-08-00286">56</xref>]. There is a cross-talk between the target genes of p53 and TLRs, and they together mediate the downstream signaling [<xref ref-type="bibr" rid="B57-biomedicines-08-00286">57</xref>]. In the patients with mutant p53, the TLR4 expression inversely correlates with the survival time, and in the WT p53 patients, the TLR4 expression correlates directly with the survival time [<xref ref-type="bibr" rid="B58-biomedicines-08-00286">58</xref>]. TLR8 is a target of p53 where its expression was increased due to a single nucleotide polymorphism (SNP) (rs3761624) in the TLR8 promoter [<xref ref-type="bibr" rid="B59-biomedicines-08-00286">59</xref>]. In another study, a comparison of the expression of TLR1-TLR10, p53, and NF-κB in patients of oral lichenoid disease (OLD) with healthy individuals was interpreted. It was found that all TLRs and p53 were increased in OLD versus healthy individuals in all the layers. Moreover, a positive correlation was obtained between the expression of TLR5, NF-κB, and p53 in the intermediate layer in OLD patients [<xref ref-type="bibr" rid="B60-biomedicines-08-00286">60</xref>]. Thus, there is a cross-talk between TLRs and p53 in the pathology of OLD. TLR4 is important in vascular inflammation, atherosclerosis, and diabetes. In the study to identify the role of palmitate-triggered apoptosis in the activation of TLR4 associated pathways, it was found that the palmitate promoted apoptosis in vascular smooth muscle cells (VSMC) and significantly enhanced the expression of p53. The knockdown of TLR4 led to a reduction in the expression of p53 in this model, directing towards the role of the TLR4/p53 axis in atherosclerosis [<xref ref-type="bibr" rid="B61-biomedicines-08-00286">61</xref>]. Further, imiquimod (IMQ) is a synthetic TLR7 ligand used for the treatment of basal cell carcinoma (BCC). A thorough study was carried out in order to understand the role of p53 in IMQ triggered cell death in the skin cancer model. It was identified that IMQ could lead to the upregulation of p53 expression, its phosphorylation, and translocation in a TLR7/8-independent manner [<xref ref-type="bibr" rid="B62-biomedicines-08-00286">62</xref>].</p>
</sec>
</sec>
<sec id="sec3-biomedicines-08-00286">
<title>3. p53 in the Tumor Microenvironment and Cancer Immunotherapy</title>
<p>The tumor microenvironment is very important in determining the fate of the tumor and its progression. One of the factors that shape the tumor microenvironment is p53. It has recently been shown that a loss of p53 can dramatically affect the immune cell composition of tumors [<xref ref-type="bibr" rid="B63-biomedicines-08-00286">63</xref>,<xref ref-type="bibr" rid="B64-biomedicines-08-00286">64</xref>] (<xref ref-type="fig" rid="biomedicines-08-00286-f001">Figure 1</xref>). The tumor-promoting macrophages are recruited in breast cancer, prostate cancer, and ovarian cancer with the loss of p53 [<xref ref-type="bibr" rid="B63-biomedicines-08-00286">63</xref>,<xref ref-type="bibr" rid="B64-biomedicines-08-00286">64</xref>,<xref ref-type="bibr" rid="B65-biomedicines-08-00286">65</xref>]. On the other hand, p53 loss increases the response of tumor-associated macrophages (TAMs) to a variety of tumor types such as lung, pancreatic, ovarian, and carcinogen-induced skin cancers [<xref ref-type="bibr" rid="B65-biomedicines-08-00286">65</xref>,<xref ref-type="bibr" rid="B66-biomedicines-08-00286">66</xref>]. In the breast cancer model, the loss of p53 has been shown to involve the malfunctioning of the WNT pathway and infiltration of neutrophils, which supports cancer progression [<xref ref-type="bibr" rid="B63-biomedicines-08-00286">63</xref>]. The infiltration of monocytes in the ascites of ovarian cancer is observed in p53 null state, probably due to the involvement of the C-C motif chemokine ligand 2 (CCL2) [<xref ref-type="bibr" rid="B65-biomedicines-08-00286">65</xref>]. In p53 null tumors, the infiltration of tumor-suppressive myeloid CD11b<sup>+</sup> cells and Treg was observed. The expression of C-C chemokine receptor type 2 (CCR2) associated chemokine and macrophage colony-stimulating factor (M-CSF) were responsible for blunting the immune response by targeting T helper and T cytotoxic cells [<xref ref-type="bibr" rid="B67-biomedicines-08-00286">67</xref>]. Thus, tumor cells get the advantage of manipulating the immune microenvironment by the loss of p53 or the accumulation of mutations in p53 [<xref ref-type="bibr" rid="B39-biomedicines-08-00286">39</xref>].</p>
<sec>
<title>p53 as a Target for Cancer Immunotherapy</title>
<p>Since p53 is highly regarded as a mutated gene in tumors, it can act as a target for cancer immunotherapy. Due to the intracellular localization of p53, targeting through antibodies was not possible. However, in a recent study, a novel antibody T1-116C was generated, which acts as a TCR mimic. This antibody recognizes several cancer types without recognizing normal blood cells. In the breast cancer xenograft model, it was showed to significantly reduce tumor growth [<xref ref-type="bibr" rid="B68-biomedicines-08-00286">68</xref>]. A similar approach with affinity matured human antibody, P1C1TM, was shown to be effective in reducing the tumor growth both in vitro and in vivo [<xref ref-type="bibr" rid="B69-biomedicines-08-00286">69</xref>]. In a recent report, the role of p53 in systemic inflammation was deciphered. In the breast cancer models, a loss of p53 in cancer cells led to an increase in WNT ligands, which triggered the macrophages to produce interleukin 1 beta (IL-1β) that ultimately led to systemic inflammation. Thus, this study was a direct demonstration of p53 as a mediator of inflammation, neutrophilia, and metastasis [<xref ref-type="bibr" rid="B63-biomedicines-08-00286">63</xref>].</p>
<p>Constitutive activation of the signal transducer and activator of transcription 3 (STAT3) pathway is an important factor in determining the tumor stroma and hence considered as a potential target for cancer immunotherapy [<xref ref-type="bibr" rid="B70-biomedicines-08-00286">70</xref>]. It is known that the loss of p53 leads to constitutive activation of the STAT3 pathway in pancreatic cancer. Moreover, the mutations in <italic>p53</italic> genes in human pancreatic cancer correlate with the poor prognosis and survival time [<xref ref-type="bibr" rid="B71-biomedicines-08-00286">71</xref>]. In addition, the ablation of p53 also leads to enhanced reactive oxygen species (ROS) production that inhibits Src homology region 2 (SHP2) activation and triggers STAT3 expression [<xref ref-type="bibr" rid="B71-biomedicines-08-00286">71</xref>]. In a phosphatase and tensin homolog (PTEN) knockout mouse and embryonic fibroblasts, p53 deficiency led to an increase in STAT3-myc signaling [<xref ref-type="bibr" rid="B72-biomedicines-08-00286">72</xref>]. STAT3 is negatively regulated by suppressors of cytokine signaling 1 (SOCS1) protein that binds to the N-terminal domain of p53, leading to cell cycle arrest and senescence [<xref ref-type="bibr" rid="B73-biomedicines-08-00286">73</xref>]. One of the mutants of p53, R175H, has been shown to enhance NF-κB signaling and increased localization to one of its subunits p65 [<xref ref-type="bibr" rid="B74-biomedicines-08-00286">74</xref>]. Some of the mutants of p53 proteins also directly interact with p65 leading to increasing NF-κB transcriptional activity [<xref ref-type="bibr" rid="B75-biomedicines-08-00286">75</xref>]. It has shown that the mutant p53 protein inhibits the expression of secreted interleukin-1 receptor antagonist (sIL-1Ra) and, thus, promotes malignancy. sIL-1Ra is a target gene for mutp53 and thus, a potential therapeutic target for combating tumor growth [<xref ref-type="bibr" rid="B76-biomedicines-08-00286">76</xref>]. <italic>TP53</italic> gene mutation is frequent in hepatocellular carcinoma (HCC). As discussed earlier, p53/mir-34a/PD-L1 and TLRs can also be considered as targets for cancer immunotherapy.</p>
</sec>
</sec>
<sec id="sec4-biomedicines-08-00286">
<title>4. Chronic Inflammation and Cancer</title>
<p>Invasion of pathogens, increased toxicity in the cells, or tissue injuries are some of the traumas that the human body combats with the progression of inflammation. Activation of inflammation is initiated by immune cells such as mast cells and macrophages, and progressively results in the production of inflammatory mediators, such as pro-inflammatory cytokines and chemokines, whose roles are to amplify the inflammatory response in order to resolve the trauma [<xref ref-type="bibr" rid="B77-biomedicines-08-00286">77</xref>]. Collectively, these inflammatory reactions lead to the release of ROS and reactive nitrogen species (RNS), in attempts to aim for tissue repairing by cellular and immune changes concluding in the amendments of the site of injured cells by cell proliferation [<xref ref-type="bibr" rid="B78-biomedicines-08-00286">78</xref>]. Thus, it can be noted that the purpose of inflammation is to solve the cellular impairments and restore cellular homeostasis. Similar to every homeostatic maintenance behavior, the initial process should be able to shut down after the resolution of the initiator. Therefore, in this case, after the restoration of the damaged tissue by the regular rate of cell growth, the inflammatory processes should be able to suspend and establish inflammation resolution through multiple mechanisms. One for instance, is moving from pro-inflammatory to anti-inflammatory reactions by the intervention of the released ROS [<xref ref-type="bibr" rid="B79-biomedicines-08-00286">79</xref>]. However, if the ability of the inflammation is not resolvable, it results in the building up of the inflammatory response products, and transformation from acute inflammation to prolonged chronic inflammation. Another source of chronic inflammation has been identified as when the acute inflammatory processes are unable to rectify the cellular damages, thus becoming uncontrolled and chronic, which further play a role in the development of chronic inflammatory diseases [<xref ref-type="bibr" rid="B80-biomedicines-08-00286">80</xref>]. In chronic inflammation, the immune cells maintain a pro-inflammatory nature, aggravating the by-products released by the immune cells, which co-results in continuous uncontrolled cell proliferation. ROS and RNS are two such by-products that are considered to aid in chronic inflammation-related cancer [<xref ref-type="bibr" rid="B81-biomedicines-08-00286">81</xref>]. Additionally, ROS and RNS are sources of DNA mutations, as they generate peroxynitrite. Peroxynitrite has been defined to possess mutagenic properties such as DNA strand lesions and nitration of the guanine bases [<xref ref-type="bibr" rid="B82-biomedicines-08-00286">82</xref>]. The 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) and 8-nitroguanine are the examples of the DNA breakages formed by the ROS and RNS, which are known to exhibit DNA mutations and have been indicated in inflammation-associated cancer [<xref ref-type="bibr" rid="B83-biomedicines-08-00286">83</xref>]. Furthermore, experimentations performed over two decades revealed that when human bronchial epithelial cells are exposed to high levels of nitric oxide (representative sources of RNS) which introduced superoxide ions, this resulted in transition mutations of the C:G pair to a T:A pair at the 248th codon of the <italic>p53</italic> gene [<xref ref-type="bibr" rid="B84-biomedicines-08-00286">84</xref>]. Whereas, it can be observed that the chronic inflammation is leading the pathway towards carcinogenesis (<xref ref-type="fig" rid="biomedicines-08-00286-f002">Figure 2</xref>). It has been stated earlier in multiple literatures that at every stage of carcinogenesis, like cell multiplications, inhibition of senescence, resistance against anti-growth signals, and metastasis, chronic inflammation is the promoter for cancer [<xref ref-type="bibr" rid="B78-biomedicines-08-00286">78</xref>,<xref ref-type="bibr" rid="B81-biomedicines-08-00286">81</xref>]. Along with being mentioned as a promoter of cancer, it has also been made evident that in cells with chronic inflammation, there is a depravity of cell repair and cell death mechanisms, and instead of a promotion of abnormal cell proliferation [<xref ref-type="bibr" rid="B85-biomedicines-08-00286">85</xref>].</p>
<p>Several immunomodulatory protein families are also implicated in inflammation. One such protein family is Siglecs [<xref ref-type="bibr" rid="B86-biomedicines-08-00286">86</xref>]. Siglecs are receptors that are expressed on the surface of white blood cells and bind to sialic acids (Sia), a nine carbon atom monosaccharide [<xref ref-type="bibr" rid="B86-biomedicines-08-00286">86</xref>,<xref ref-type="bibr" rid="B87-biomedicines-08-00286">87</xref>,<xref ref-type="bibr" rid="B88-biomedicines-08-00286">88</xref>]. Most members of this family carry an inhibitory motif and lead to the suppression of immune response [<xref ref-type="bibr" rid="B86-biomedicines-08-00286">86</xref>,<xref ref-type="bibr" rid="B87-biomedicines-08-00286">87</xref>,<xref ref-type="bibr" rid="B88-biomedicines-08-00286">88</xref>]. Siglecs have been implicated in immunological response in many physiological and pathological conditions, including cancer [<xref ref-type="bibr" rid="B89-biomedicines-08-00286">89</xref>,<xref ref-type="bibr" rid="B90-biomedicines-08-00286">90</xref>,<xref ref-type="bibr" rid="B91-biomedicines-08-00286">91</xref>,<xref ref-type="bibr" rid="B92-biomedicines-08-00286">92</xref>,<xref ref-type="bibr" rid="B93-biomedicines-08-00286">93</xref>,<xref ref-type="bibr" rid="B94-biomedicines-08-00286">94</xref>]. In the case of a tumor, the cancer cells start to overexpress sialic acid, and the engagement of Siglecs on immune cells leads to immunoevasion and ultimately enhanced tumor growth [<xref ref-type="bibr" rid="B90-biomedicines-08-00286">90</xref>,<xref ref-type="bibr" rid="B91-biomedicines-08-00286">91</xref>]. A few members of the Siglec family are also activating in nature, and the engagement of these receptors leads to enhanced immune response and reduced tumor growth [<xref ref-type="bibr" rid="B92-biomedicines-08-00286">92</xref>,<xref ref-type="bibr" rid="B95-biomedicines-08-00286">95</xref>]. As priorly mentioned, oxidative stresses contributed by the inflammatory mediators and their by-products, seem to act as crucial protagonists in the development of carcinogenesis. Once inflammation-mediated cancer is established, it gears in pathways to strive onwards with the tumorigenic activities. One such pathway is the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway that regulates the cancerous development.</p>
<sec>
<title>NRF2 Pathway and Its Role in Cancer</title>
<p>At normal conditions, Nrf2 acts as the transcription factor that binds the anti-oxidant response element (ARE) that initiates the expression of anti-oxidant and cytoprotective enzymes. The Nrf2 factor is maintained at a dormant phase by its negative regulator: the kelch-like ECH associated protein (Keap1)-Cullin 3 based ligase (CUL3) complex [<xref ref-type="bibr" rid="B96-biomedicines-08-00286">96</xref>]. The Keap1-CUL3 complex sustains lower levels of Nrf2 by ubiquitination and proteasomal degradation, keeping it in a silenced phase [<xref ref-type="bibr" rid="B97-biomedicines-08-00286">97</xref>]. Normally, Nrf2 is induced with increased oxidative stress, where it detaches from the Keap1-CUL3 complex, halting their antagonistic activity, enters the nucleus, binds to the ARE, and consequently expresses greater than 200 genes for anti-oxidative pathways [<xref ref-type="bibr" rid="B98-biomedicines-08-00286">98</xref>]. However, in chronic inflammation-induced oxidative stress, the Nrf2 can escape its negative regulation performed by Keap1 by direct cause of increased oxidative stress that results in the upregulation of the p6 protein: an activator of Nrf2, and subsequently dismantles autophagocytosis of the p6 protein [<xref ref-type="bibr" rid="B99-biomedicines-08-00286">99</xref>]. Nrf2 activity has been known to be exemplified by inhibiting the activities of Keap1 directly, such as p21Cip/WAF1, a competitive inhibitor of Keap1, inhibiting it from attaching to the DLG functional domain of Nrf2, thereby disrupting its ability of Nrf2 degradation [<xref ref-type="bibr" rid="B100-biomedicines-08-00286">100</xref>]. Thus, it can be concluded that in chronic oxidative stresses, there is a hyper-regulation of Nrf2 activation. Similarly, when dealing with chronic inflammation-mediated cancers, there has been evidence that the Nrf2 factors are overexpressed, which could be due to mutations, changes in DNA methylation patterns, and protein alterations [<xref ref-type="bibr" rid="B101-biomedicines-08-00286">101</xref>]. Carcinogenic promoting properties are harnessed by the Nrf2 in cancer cells, playing vicious roles in promoting cell proliferation, inhibiting apoptosis, and strengthening its resistance to chemo/radiotherapy [<xref ref-type="bibr" rid="B102-biomedicines-08-00286">102</xref>]. One other interesting property imparted by Nrf2 to cancerous cells is drug resistance. It has been found in doxorubicin-resistant human ovarian cancer cells, the upregulation of Nrf2 resonates with its character of resistance [<xref ref-type="bibr" rid="B103-biomedicines-08-00286">103</xref>]. Moreover, it has been described as a promoter of all the necessary key hallmarks needed to establish cancer, from increasing protein synthesis and expression of cell division genes to stimulating mRNA translations in support of cell proliferation [<xref ref-type="bibr" rid="B96-biomedicines-08-00286">96</xref>].</p>
</sec>
</sec>
<sec id="sec5-biomedicines-08-00286">
<title>5. Oxidative Stress, p53, and Inflammation</title>
<p>Oxidative stress is referred to as a state of imbalanced equilibrium between the generation of ROS with the anti-oxidant system of the body [<xref ref-type="bibr" rid="B104-biomedicines-08-00286">104</xref>]. A balanced redox mechanism is necessary for maintaining genomic integrity. Excessive oxidative stress can cause immune dysfunction and, thereby, induce an inflammatory response. For instance, the immune cells, such as T lymphocyte activation, were found to be suppressed by excessive ROS leading to inflammation and tumorous conditions. ROS, therefore, plays a dual role by either suppressing T lymphocyte activation or its intermediate level modulate T lymphocyte differentiation at the site of injury. Contrastingly, a persistent level of ROS enhances apoptosis in T cell lymphocytes by damaging DNA through a p53 pathway [<xref ref-type="bibr" rid="B105-biomedicines-08-00286">105</xref>]. Several methods have been adopted to sensitize T lymphocytes to the site of injury and inflammation. Amongst these, the use of polyphenol such as resveratrol was found to boost T lymphocytes significantly in mice by enhancing CD86 and MHC-II antigens [<xref ref-type="bibr" rid="B106-biomedicines-08-00286">106</xref>]. Another phytochemical, lycopene, alleviates oxidative injury in ruminant animals by inhibiting inflammatory cytokines and apoptosis. The anti-oxidant potential of lycopene ameliorates hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-induced inflammation by regulating the Nrf2-ARE pathway in primary bMEC and MAC-T cells [<xref ref-type="bibr" rid="B107-biomedicines-08-00286">107</xref>].</p>
<p>Further, in vivo studies have also shown a correlation between increased oxidative stress leading to neurobehavioral disorders. Buthionine sulfoximine (BSO)-induced oxidative stress in BTBR T<sup>+</sup> tf/J (BTBR) mice have resulted in depletion of the native enzymatic anti-oxidant system, which has resulted in autism-like repetitive behaviors [<xref ref-type="bibr" rid="B108-biomedicines-08-00286">108</xref>]. A systemic review also suggested that an imbalanced redox potential may contribute to neurodegenerative diseases by altering differentiation and the number of CD4<sup>+</sup> T cell subpopulations [<xref ref-type="bibr" rid="B109-biomedicines-08-00286">109</xref>]. Several reports indicated that oxidative stress-mediated inflammation could lead to cancer progression. Activation of transcription factors including NF-κB, AP-1, p53, HIF-1α, PPAR-γ, β-catenin/Wnt, and Nrf2 can transform normal cells into cancerous cells. Furthermore, a cross-talk between NF-κB activation and cell proliferation regulates the immunological and inflammatory response resulting in tumor conditions [<xref ref-type="bibr" rid="B110-biomedicines-08-00286">110</xref>]. Such reports also indicated the possibility of using NF-κB as a prognostic marker to identify cancers, in particular, colon cancer [<xref ref-type="bibr" rid="B111-biomedicines-08-00286">111</xref>]. It is noteworthy to observe that these transcriptional factors mediate p53-dependent fashion in response to an inflammatory condition.</p>
<p>Oxidative stress-induced p53 activation is common in inflammation and cancers. Activation of p53 primarily regulates the cell cycle, DNA repair, and apoptotic mechanisms [<xref ref-type="bibr" rid="B112-biomedicines-08-00286">112</xref>]. Cancer cells exhibit higher ROS levels than normal cells since they are serving as an oncogenic agent with increased metabolism and mutation rates [<xref ref-type="bibr" rid="B113-biomedicines-08-00286">113</xref>]. DNA damage caused by chemotherapeutic drugs, environmental and chemical toxins, radiations, and immunosuppressive drugs often elevates ROS levels, leading to p53 activation. Homeostatic regulation of ROS and p53 is necessary to determine the fate of normal tissue stem cells. Recent data have shown the direct relationship between ROS and p53 for the differentiation of stem cells. The lack of p53 functioning in the neural progenitor cells leads to increased ROS and premature differentiation [<xref ref-type="bibr" rid="B114-biomedicines-08-00286">114</xref>]. Meanwhile, restoring ectopic expression of p53, and with anti-oxidants, enhances partial differentiation and stemness [<xref ref-type="bibr" rid="B115-biomedicines-08-00286">115</xref>]. Many data have shown the dual mode of p53 functioning depending on the nature, duration, and intensity of oxidative stress imposed in different cell types. Hence, either anti-oxidant or pro-oxidant regulatory functioning of p53 is well known, depending on the type of cell burden. Activation of p53 by anti-oxidants imposes a protective mechanism against oxidative stress by ameliorating excessive ROS levels in the cells. Further, both endogenous and exogenous supply of anti-oxidants could play a role in inhibiting adhesion and invasion properties of cancer cells [<xref ref-type="bibr" rid="B116-biomedicines-08-00286">116</xref>,<xref ref-type="bibr" rid="B117-biomedicines-08-00286">117</xref>]. In contrast, pro-oxidants exert oxidative stress-induced p53 functioning leading to autophagy, caspase-mediated apoptosis, and necrotic cell death mechanisms [<xref ref-type="bibr" rid="B118-biomedicines-08-00286">118</xref>,<xref ref-type="bibr" rid="B119-biomedicines-08-00286">119</xref>]. A detailed analysis of anti-oxidant versus pro-oxidant effects on p53 mediated functioning is discussed elsewhere [<xref ref-type="bibr" rid="B116-biomedicines-08-00286">116</xref>,<xref ref-type="bibr" rid="B120-biomedicines-08-00286">120</xref>].</p>
</sec>
<sec id="sec6-biomedicines-08-00286">
<title>6. Plant Flavonoids as Therapeutic Agents</title>
<p>Over the last two decades, plant polyphenols, especially flavonoids, have gained significant attention in developing treatments for disorders such as Parkinson’s disease, inflammatory bowel disease, Alzheimer’s disease, obesity, cancer, and cardiovascular diseases (CVDs) [<xref ref-type="bibr" rid="B121-biomedicines-08-00286">121</xref>,<xref ref-type="bibr" rid="B122-biomedicines-08-00286">122</xref>]. A plethora of research has been done already to show how flavonoids influence these diseased conditions, mostly with their biochemical and pharmacological properties such as pro-oxidant and anti-oxidant potentials that correlates to their structure–activity relationship. Plant flavonoids share a basic structure of diphenyl propane in which two benzene rings are connected through a pyran ring. The subclasses of flavonoids such as flavones, flavonols, isoflavones, anthocyanin, flavan-3-ols, and flavanones differ by the attachment of carbon on the C ring to which the B ring is attached (<xref ref-type="fig" rid="biomedicines-08-00286-f003">Figure 3</xref>) [<xref ref-type="bibr" rid="B123-biomedicines-08-00286">123</xref>]. Further, the degree of unsaturation and oxidation of the C ring contributes to the different classifications of flavonoids.</p>
<p>The structure-activity relationship of flavonoids majorly attributes to their observed clinical effects both in in vitro and in vivo studies. For instance, an anti-oxidant property of a flavonoid largely depends on the functional group it possesses and its spatial arrangement around the nucleus. The importance of the B ring and the hydroxyl group at position 3 often contributes to ROS scavenging potentials, as evident by the experimental and theoretical derivations. Furthermore, this spatial arrangement of the functional group and its substitution, along with the number of sugar moieties (glycosides) and hydroxyl groups, determines the mechanism of anti-oxidant potentials observed for several flavonoids [<xref ref-type="bibr" rid="B124-biomedicines-08-00286">124</xref>,<xref ref-type="bibr" rid="B125-biomedicines-08-00286">125</xref>]. Anti-oxidants exert various radical scavenging properties either by inhibiting chelated trace elements or enzymes that generate excessive ROS and/or by enhancing endogenous anti-oxidant enzymes such as glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). In contrast, the pro-oxidant effect of flavonoids can result in preventing cancer through inhibiting the proliferation of tumor cells with apoptotic induction. Recent structure–activity studies have shown that the flavonoids possess significant anti-proliferative effects, especially in the presence of di-OH 3′, 4′, a double bond at C2-C3 and a carbonyl at the C4 position. However, flavonoids that possess functional chemical moiety at the C7-C8 position showed low to non-significant anti-proliferative effects [<xref ref-type="bibr" rid="B126-biomedicines-08-00286">126</xref>]. These observations further warrant discussions on the importance of flavonoids in treating disease, especially inflammation and cancer, which are discussed below.</p>
</sec>
<sec id="sec7-biomedicines-08-00286">
<title>7. Flavonoids in Inflammation and Cancer Prevention</title>
<p>The p53-mediated pathway has been an attractive target for many of the flavonoids in regulating inflammation and cancers. Flavonoids regulate transcription factors such as NF-κB, Nrf2, and AP-1 in inflammation and DNA damage, cell cycle, and apoptosis in tumor cell proliferation. We have reviewed dietary flavonoids such as quercetin, luteolin, cyanidin, daidzein, and epigallocatechin gallate (EGCG) along with other flavonoids, which showed promising results in preclinical and clinical trials. While many reviews are available on discussing how different flavonoids can be used to induce apoptosis in cancer models, we have focused on flavonoids and their ability to prevent inflammation and cancers with a focus on p53-mediated mechanisms.</p>
<sec id="sec7dot1-biomedicines-08-00286">
<title>7.1. Quercetin</title>
<p>Quercetin, a flavonol found in vegetables and fruits, has been reported for various pharmacological properties that include scavenging ROS, inhibiting inflammation, and preventing cancer. One of the mechanisms by which quercetin exerts cytoprotective effects is through regulating MEK/ERK and Keap1/Nrf2/ARE pathways in inflammation [<xref ref-type="bibr" rid="B127-biomedicines-08-00286">127</xref>]. An in vitro study has shown the protective effect of quercetin in cigarette smoke extract-induced inflammation by downregulating cytokine markers such as IL-1β, IL-6, and IL-8 in ARPE-19 cells. Pretreatment with quercetin further activates the Keap1/Nrf2/ARE-anti-oxidant pathway, which induces cellular defenses against various oxidative stress [<xref ref-type="bibr" rid="B128-biomedicines-08-00286">128</xref>]. Recent reports have shown that p53 can activate the Keap1/Nrf2/ARE-anti-oxidant pathway and can act as the main regulator of the cells anti-oxidant response [<xref ref-type="bibr" rid="B129-biomedicines-08-00286">129</xref>,<xref ref-type="bibr" rid="B130-biomedicines-08-00286">130</xref>]. This effect of p53 largely depends on the intensity and degree of oxidative stress imposed. A lower level of oxidative stress has been correlated with increased anti-oxidant enzymes, such as SOD and CAT [<xref ref-type="bibr" rid="B131-biomedicines-08-00286">131</xref>]. A flavonoid-rich extract from <italic>Rosa laevigata</italic> Michx fruit exerts neuroprotective effects by downregulating the levels of p-JNK, p-ERK, and p-p38 in MAPK pathways [<xref ref-type="bibr" rid="B132-biomedicines-08-00286">132</xref>]. Furthermore, various in vivo studies in mice and rats have shown the downregulation of anti-inflammatory markers with increased anti-oxidant defense proteins (SOD, CAT, GPx) under oxidative stress-induced conditions, such as adipose hypertrophy, hepatocarcinogenesis, and obesity-induced skeletal muscle inflammation [<xref ref-type="bibr" rid="B133-biomedicines-08-00286">133</xref>,<xref ref-type="bibr" rid="B134-biomedicines-08-00286">134</xref>]. Further, quercetin significantly reduces adipocyte size and enhanced angiogenesis and adipogenesis by downregulating TNFα and HIF-1 α levels along with proteins such as TLR-4, CD68, MCP-1, and JNK [<xref ref-type="bibr" rid="B135-biomedicines-08-00286">135</xref>].</p>
<p>Quercetin has been extensively studied to explore its mechanism of action in cancer prevention. Treatment with quercetin was reported to protect DNA damage induced by H<sub>2</sub>O<sub>2</sub> in human Caco-2 cells. Quercetin decreases single-strand DNA breaks by enhancing the expression of human 8-oxoguanine DNA glycosylase and DNA repair mechanisms [<xref ref-type="bibr" rid="B136-biomedicines-08-00286">136</xref>]. However, the detailed mechanism of p53 involvement in cancer prevention by quercetin remains unclear. It is believed that upon regulating p53 mechanisms, quercetin possesses a dual role and can have better control over cellular events to mitigate oxidative stress imposed by carcinogens through activating the Keap1/Nrf2/ARE anti-oxidant pathway and/or inducing apoptosis. In a recent study by Wang et al., quercetin was able to inhibit apoptosis by downregulating p53, Bax, and caspase-3 expression in ARPE-19 cells, and, thereby, it prevents high glucose-induced injury [<xref ref-type="bibr" rid="B137-biomedicines-08-00286">137</xref>]. A similar kind of protective effect was also noted in the study by Darband et al., in which quercetin was able to inhibit oxidative DNA damage by activating the Nrf2 signaling pathway. Supplementation of quercetin (50 mg/kg) in rats reduces colon carcinogenesis induced by 1,2-dimethylhydrazine (DMH) [<xref ref-type="bibr" rid="B138-biomedicines-08-00286">138</xref>]. In contrast, a study by Clemente-Soto et al., demonstrated the activation of p53 upon quercetin treatment in cervical cancer cells leading to apoptosis and DNA damage [<xref ref-type="bibr" rid="B139-biomedicines-08-00286">139</xref>]. There are several reports available to demonstrate the similar functioning of p53-induced apoptosis, leading to cancer growth inhibition and prevention. This could be attributed to the multiple facts that the quercetin binding potentials to several receptors that may be important in the prevention of carcinogenesis, induces epigenetic modifiers, and interferes with enzymes such as native anti-oxidants, to elicit its protective mechanisms. Despite these properties, quercetin could sensitize and protect noncancerous cells during chemotherapy or radiotherapy when used in combination with existing classes of cancer chemotherapeutic-drugs [<xref ref-type="bibr" rid="B140-biomedicines-08-00286">140</xref>].</p>
</sec>
<sec id="sec7dot2-biomedicines-08-00286">
<title>7.2. Luteolin</title>
<p>Luteolin, a flavone found in many plants such as <italic>Salvia tomentosa</italic> Mill. (Balsamic sage) and <italic>Glossogyne tenuifolia</italic> possess anti-inflammatory effects via downregulating the NF-κB pathway. Luteolin was found to inhibit inflammation induced by infectious pathogens such as <italic>Staphylococcus aureus</italic> to cause mastitis. Treatment with luteolin reduces cytokines expression such as TNF-α, IL-1β, and IL-6 in a mouse model mimicking mastitis. Furthermore, luteolin suppressed the expression of IκBα and NF-κB, along with matrix metalloprotease-2 (MMP-2) and MMP-9, to render protection against inflammation [<xref ref-type="bibr" rid="B141-biomedicines-08-00286">141</xref>]. A recent report showed the protective effect of luteolin against testicular deficits caused by lead acetate. Luteolin (50 mg/kg) treatment in male Wistar rats significantly activates the Nrf2/HO-1 pathway by increasing native anti-oxidant enzymes and inhibits inflammatory and apoptotic cascades [<xref ref-type="bibr" rid="B142-biomedicines-08-00286">142</xref>]. These protective effects could relate to the anti-oxidant potential of luteolin [<xref ref-type="bibr" rid="B143-biomedicines-08-00286">143</xref>] and it’s functioning on the p53 protein, as it is suppressed in <italic>Staphylococcus aureus</italic>-induced inflammation, preventing apoptosis [<xref ref-type="bibr" rid="B144-biomedicines-08-00286">144</xref>]. Furthermore, a study by Li et al., proved the anti-oxidant nature of luteolin by activating the Nrf2 signaling pathway and NF-κB-mediated inflammatory responses in type 1 diabetes in mice. Modulation of these pathways reduces MMP protein expression and cellular hypertrophy [<xref ref-type="bibr" rid="B145-biomedicines-08-00286">145</xref>]. These studies show that the protective effect of luteolin against inflammation largely depends on its anti-oxidant nature rather than its pro-oxidant effect, which inhibits different cancer cell proliferation [<xref ref-type="bibr" rid="B143-biomedicines-08-00286">143</xref>].</p>
<p>Luteolin exerts its cancer-preventive properties by inhibiting DNA damage and activating anti-oxidant mechanisms in a p53 regulated manner. Combinational treatment of luteolin and EGCG showed translocation of p53 to the mitochondria, thereby regulating apoptosis [<xref ref-type="bibr" rid="B146-biomedicines-08-00286">146</xref>]. This translocation of p53 is crucial and depends on the degree of stress burden imposed. The mitochondrial translocation occurs if the damage or stress is irreversible [<xref ref-type="bibr" rid="B147-biomedicines-08-00286">147</xref>]. Further, in a study by Jiang et al., luteolin exerts its tumor-preventive potential by regulating the expression of microRNAs (miRNAs). Treatment in non-small cell lung cancer cell lines reduced cell proliferation and tumor inhibition in the H460 xenograft tumor model. The expression of an enhanced miR-34a-5p level was observed in tumor tissues, which resulted in a reduced level of MDM4 proteins. Furthermore, luteolin treatment enhanced p53 and p21 expression and reduced tumorigenesis [<xref ref-type="bibr" rid="B148-biomedicines-08-00286">148</xref>]. The isolated compound luteolin from <italic>Melissa officinalis</italic> L, showed DNA damage protective effects induced by ultraviolet B radiation (UVB) in skin cells. Treatment with luteolin reduced DNA double strand breaks and the DNA damage response (DDR) mechanism in these cells [<xref ref-type="bibr" rid="B149-biomedicines-08-00286">149</xref>]. Many studies have shown the upregulation of p53-mediated apoptosis for tumor inhibition in various cancer cell lines [<xref ref-type="bibr" rid="B150-biomedicines-08-00286">150</xref>,<xref ref-type="bibr" rid="B151-biomedicines-08-00286">151</xref>] and are not in the scope for this review.</p>
</sec>
<sec id="sec7dot3-biomedicines-08-00286">
<title>7.3. EGCG</title>
<p>An anti-oxidant potent flavan-3-ol, EGCG, mostly seen in green tea polyphenols, showed anti-inflammatory effects under imposed oxidative stress conditions. EGCG exhibited an anti-inflammatory effect by inhibiting pro-inflammatory cytokines’, p53, NF-κB, TLRs, and STAT3 expression. In a recent study by Wang et al., rats were administrated with EGCG (50 mg/kg) and analyzed for parameters for anxiety-like behavior and myocardial infarction. ELISA and PCR studies have shown a significant reduction of IL-6 along with STAT3 expression. Further, inhibition of apoptosis cascades (caspase expression) was observed in rats. Hence, the intake of EGCG reversed anxiety-like behavior and prevented inflammation [<xref ref-type="bibr" rid="B152-biomedicines-08-00286">152</xref>]. Similar observations were made by Ren et al., wherein lipopolysaccharides (LPS)-induced retinal inflammation in rats was attenuated by green tea extract (containing EGCG) through inhibiting phosphorylation of STAT3 and NF-κB along with pro-inflammatory cytokines [<xref ref-type="bibr" rid="B153-biomedicines-08-00286">153</xref>]. Further reports have shown a strong association between EGCG and TLRs, which play an important role in the host immune system. TLR4 has a strong relation with inflammatory response and cancer progression [<xref ref-type="bibr" rid="B154-biomedicines-08-00286">154</xref>]. It is interesting to observe that the p53-mediated differential expression of TLR4 depends on the context of the cells. In p53 wild type cells, the activation of TLR4 results in type-I IFN (IFN-γ) secretion, resulting in p21 mediated cell cycle arrest. Whereas in p53 mutant cells, the activation of TLR4 promotes cancer [<xref ref-type="bibr" rid="B58-biomedicines-08-00286">58</xref>]. EGCG was shown to inhibit TLR4 expression in in vitro and in vivo studies [<xref ref-type="bibr" rid="B155-biomedicines-08-00286">155</xref>,<xref ref-type="bibr" rid="B156-biomedicines-08-00286">156</xref>]. However, EGCG’s direct involvement in p53-mediated regulation of TLR4 is not fully understood.</p>
<p>EGCG, being an active anti-oxidant, protects DNA damage mediated cell death in many cells. As observed for other flavonoids, EGCG exerts its preventive potentials by modulating Nrf2 and JAK/STAT pathways in testicular ischemia reperfusion injury-induced oxidative damage. Pre-perfusion treatment with EGCG prevented phosphorylation of JAK2, STAT3, and STAT1 along with apoptotic markers [<xref ref-type="bibr" rid="B157-biomedicines-08-00286">157</xref>]. Likewise, EGCG prevents apoptosis and astrogliosis induced by acrylamide in rats. Pretreatment in rats with EGCG showed reduced DNA fragmentation, Bax, Bcl-2, caspase 3, and cytochrome c expression. Further, EGCG enhanced native anti-oxidant enzymes and glutathione levels to mitigate excessive ROS production [<xref ref-type="bibr" rid="B158-biomedicines-08-00286">158</xref>]. EGCG was also shown to modulate DNA methylation processes, especially DNA methyltransferase 1, thereby rendering DNA protection [<xref ref-type="bibr" rid="B159-biomedicines-08-00286">159</xref>]. Genomic stability of the cells can be safeguarded against various carcinogens by consuming flavonoids. Detailed mechanisms on DNA damage response and prevention are discussed elsewhere [<xref ref-type="bibr" rid="B160-biomedicines-08-00286">160</xref>,<xref ref-type="bibr" rid="B161-biomedicines-08-00286">161</xref>].</p>
</sec>
<sec id="sec7dot4-biomedicines-08-00286">
<title>7.4. Cyanidin</title>
<p>Cyanidin, an anthocyanidin, found in plant pigments and berries [<xref ref-type="bibr" rid="B162-biomedicines-08-00286">162</xref>] including grapes, bilberry, and blackberry, has been found to possess anti-inflammatory effects under oxidative stress conditions. Cyanidin-3-glucoside (C3G) is a naturally occurring anthocyanin in plants and cyanidin is the aglycone of C3G. Both C3G and cyanidin have shown significant anti-inflammatory effects against 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in mice. Administration of 200 μmol/kg in mice reduces inflammatory markers (TNF-α, IL-1β, IL-6, and interferon-γ) and thereby protecting the intestinal barrier [<xref ref-type="bibr" rid="B163-biomedicines-08-00286">163</xref>]. Similarly, in vitro effects have been studied on Caco-2 cells, which showed inhibition in the disruption of intestinal barrier dysfunction. Further, C3G was found to improve diabetic conditions, especially diabetic nephropathy (DN). Eight weeks supplementation of 10–20 mg/kg of C3G in rats improves native oxidative enzymes and modulate the TGF-β1/Smad2/3 pathway to render renal protection [<xref ref-type="bibr" rid="B164-biomedicines-08-00286">164</xref>]. This effect was further improved by encapsulating C3G in chitosan nanoparticles for targeted drug delivery and resulted in p53 mediated protection in mice. C3G downregulated p53-mediated apoptosis in mice with a balanced B-cell lymphoma-2/leukemia-2 ratio [<xref ref-type="bibr" rid="B165-biomedicines-08-00286">165</xref>].</p>
<p>Further, C3G rendered DNA damage protection in BEAS-2B and HaCaT cells in vitro from oxidative stress imposed by nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and UVB, respectively. In both studies, the degree of DNA damage was decreased by modulating ATM/ATR pathways, which is mediated by p53 expression [<xref ref-type="bibr" rid="B166-biomedicines-08-00286">166</xref>,<xref ref-type="bibr" rid="B167-biomedicines-08-00286">167</xref>]. Treatment with C3G restores the Bcl-2 expression in HaCaT cells and inhibits caspase-3 activation. Our previous study on apple peel flavonoid fraction (AF4) containing C3G as the main constituent, showed a DNA protective effect on NNK, methotrexate (MTX), and cisplatin-induced toxicity in BEAS-2B cells. Pretreatment with AF4 reduced the ROS level with an increase in anti-oxidant enzymes. Further, AF4 reduces DNA damage and enhanced protection against carcinogens by facilitating DNA repair mechanisms [<xref ref-type="bibr" rid="B168-biomedicines-08-00286">168</xref>]. A study by Kaewmool et al., showed both anti-inflammatory and apoptotic effects of C3G in PC-12 cells. Anti-inflammation was mediated by decreased expression of IL-1β and IL-6 along with inducible nitric oxide synthase (iNOS) and Cox2 expression, while the apoptotic effect was mediated by a caspase-3 induced mechanism [<xref ref-type="bibr" rid="B169-biomedicines-08-00286">169</xref>].</p>
</sec>
<sec id="sec7dot5-biomedicines-08-00286">
<title>7.5. Daidzein</title>
<p>Daidzein, an isoflavone, found in soybeans and soy products, is known to possess anti-inflammatory and cancer-preventive properties by inhibiting various inflammatory cytokines and cell death markers, respectively. Daidzein was found to inhibit the nephrotoxicity posed by cisplatin-induced oxidative stress in proximal tubular cells of mice. Treatment with daidzein inhibits the expression of TNFα, IL-10, and IL-18 along with enhanced anti-oxidant defense enzymes (SOD and GPx) activity. Further, daidzein reduces kidney injury markers (NGAL, BUN, creatinine, and KIM-1) and cell death mechanisms (caspase-3/7) [<xref ref-type="bibr" rid="B170-biomedicines-08-00286">170</xref>]. Daidzein also improves the adverse effect of adipose inflammation by regulating the proliferator-activated receptor γ (PPARγ) in 3T3-L1 adipocytes. A decreased expression of monocyte chemoattractant protein-1 (MCP-1) and TNF-α was noted in adipose tissue of daidzein-fed mice [<xref ref-type="bibr" rid="B171-biomedicines-08-00286">171</xref>]. Similar effects were observed by Feng et al., wherein daidzein treatment in rats inhibited TLR4 and NF-κB activation leading to the prevention of inflammation [<xref ref-type="bibr" rid="B172-biomedicines-08-00286">172</xref>]. Furthermore, the synergic effect of daidzein and genistein exerts photoprotective potentials by regulating growth arrest and DNA damage (gadd45) genes, to decrease DNA damage and enhances DNA repair process in UV-induced photodamage [<xref ref-type="bibr" rid="B173-biomedicines-08-00286">173</xref>,<xref ref-type="bibr" rid="B174-biomedicines-08-00286">174</xref>]. The possible mechanisms by which flavonoids exert their anti-inflammatory and cancer-preventive properties are illustrated in <xref ref-type="fig" rid="biomedicines-08-00286-f004">Figure 4</xref>. Other flavonoids and their anti-inflammatory and cancer-prevention properties are summarized in <xref ref-type="table" rid="biomedicines-08-00286-t001">Table 1</xref>.</p>
</sec>
</sec>
<sec id="sec8-biomedicines-08-00286">
<title>8. Flavonoids and Dietary Intake</title>
<p>Recent epidemiological, cross-sectional and short-term randomized controlled studies have proved a direct relationship between flavonoid-rich diet intake and health benefits resulting in preventing various diseases. Flavonoids, with numerous potentials, as discussed above, improve life-threatening conditions, particularly cancer and CVDs. This direct correlation is based on several factors such as type/composition of flavonoid(s), their bioavailability after consumption, and the epidemiological region.</p>
<p>For instance, the average intake of flavan-3-ol among Europeans ranges between 77 mg/day to 182 mg/day probably because of the high consumption of tea, at least in the UK [<xref ref-type="bibr" rid="B201-biomedicines-08-00286">201</xref>]. A large portion of ingested flavan-3-ol remained in the large intestine as they are not readily absorbed by phase II conjugating enzymes. This availability of flavan-3-ol could benefit microbiota in the colon region to metabolize further into monomers and contribute to an enhanced immune system [<xref ref-type="bibr" rid="B202-biomedicines-08-00286">202</xref>,<xref ref-type="bibr" rid="B203-biomedicines-08-00286">203</xref>]. In other countries of Europe (except the UK), a rich flavan-3-ol diet was mostly observed because of the consumption of non-citrus fruits (apples/pears) [<xref ref-type="bibr" rid="B201-biomedicines-08-00286">201</xref>]. A meta-analysis of epidemiologic studies has shown a positive correlation between the consumption of flavan-3-ol and reduced cancer. The higher consumption of flavan-3-ol reduces rectal, oropharyngeal, breast, and laryngeal cancers [<xref ref-type="bibr" rid="B204-biomedicines-08-00286">204</xref>]. In contrast, a study among 38,408 women aged ≥45 y with a frequent diet enriched with flavonols did not correlate with cancer risk prevention. The best explanation for the discrepancy could be due to a relatively low range of flavonoid intake combined with populations free of CVDs and cancers. However, continuous efforts have been made to overcome such issues as well as lipophilic nature, low solubility, and variable bioavailability of flavonoids by introducing different formulations to nanocrystals technology [<xref ref-type="bibr" rid="B205-biomedicines-08-00286">205</xref>].</p>
<p>Another intake of flavonoids, such as anthocyanins and flavanones, exhibited a lower risk of CVDs in both women and men. A study conducted in 43,880 healthy men who have the habit of consuming a higher anthocyanin intake showed a lower risk of developing ischemic stroke over a period of 24 y [<xref ref-type="bibr" rid="B206-biomedicines-08-00286">206</xref>]. Various studies have shown that the anthocyanins exert healthy beneficial effects on LDL-cholesterol level, which is mediated by cholesterol efflux capacity [<xref ref-type="bibr" rid="B207-biomedicines-08-00286">207</xref>]. In a randomized controlled trial, anthocyanins showed anti-inflammatory effects by reducing hypercholesterolemic conditions in adults. This effect was consistent with previous observations as intake of anthocyanins significantly reduced LDL-cholesterol and HDL-cholesterol levels with inhibition of IL-6 and IL-1β in a HepG2 cell line [<xref ref-type="bibr" rid="B208-biomedicines-08-00286">208</xref>]. It is noteworthy to observe that a mixture of anthocyanins was more effective than individual components for improved human health. As discussed earlier, it could be the anti-oxidant potential of flavonoids that might exert these effects, as observed from a recent cross-sectional study conducted in the Italian population against the human papillomavirus (hrHPV) infection. The study was conducted in 251 women with normal cervical cytology, showed a significant reduction in the risk of developing hrHPV infection with anthocyanins-rich diet [<xref ref-type="bibr" rid="B209-biomedicines-08-00286">209</xref>]. Further, a flavonoid-rich diet has been studied for their protective effects against various disease conditions which are shown in <xref ref-type="table" rid="biomedicines-08-00286-t002">Table 2</xref>.</p>
<p>Moreover, the dietary intake of flavonoids has a direct impact with microbiota as ingested flavonoids are known to be unabsorbed in the proximal intestine, further reach the colon region. This microenvironment facilitates the hydrolysis and fermentation of flavonoids employing different enzymes released by the microorganisms. Microbes can facilitate oxidation, demethylation, and catabolism of flavonoids into phenolic acids and aromatic catabolites [<xref ref-type="bibr" rid="B210-biomedicines-08-00286">210</xref>]. Recent studies have shown that the high flavonoid-rich diet exerts an inverse correlation with obesity and inflammation. This is largely mediated by gut microbiota as it increases adiposity and fatty acid metabolism. Further, intestinal microbes modify flavonoids by glucosidation, dihydroxylation, and decarboxylation converting them into monomers, which can be more absorbable in the intestine [<xref ref-type="bibr" rid="B211-biomedicines-08-00286">211</xref>]. To add, flavonoids isolated from mulberry leaves ameliorate lipid dysmetabolism in the high fat diet (HFD)-fed mice. Gut microbes such as <italic>Bacteroidetes</italic> played a role in the increased production of acetic acid, thereby restoring lipid metabolism [<xref ref-type="bibr" rid="B212-biomedicines-08-00286">212</xref>]. From these observations, it is noteworthy to believe that both classifications of flavonoids and microbiota play a cross-talk between dietary intake and improved health benefits.</p>
</sec>
<sec id="sec9-biomedicines-08-00286" sec-type="conclusions">
<title>9. Conclusions and Future Directions</title>
<p>The role of p53 in inflammation and cancer is well established. Being a central protein in immune pathways, the modulation of p53 expression may lead to the prevention of many diseases. Further cross-talk between p53 and immune checkpoints, such as MHC1 and TLRs, has great potential in developing drugs, especially for cancer immunotherapy. As discussed in this review, flavonoids are one of the ideal choices of biomolecules for developing safer immunosuppresses in the management of chronic inflammation leading to cancer progression. Many of the flavonoids exert their preventive potentials by enhancing the endogenous anti-oxidant system through modulating the Keap1/Nrf2/ARE pathway. Although the p53-mediated Nrf2 pathway is not well studied, there is evidence to show that the activation of the Nrf2 pathway leads to a reduction in oxidative stress and enhanced DNA repair processes [<xref ref-type="bibr" rid="B223-biomedicines-08-00286">223</xref>]. Thus flavonoids, especially with anti-oxidant properties, enhance the immune response against various oxidative stress-mediated cellular malfunctions leading to disease prevention. Further, a flavonoid-rich diet has shown evidence for the above cytoprotective mechanism in recent clinical trials, showing their disease-preventive potential.</p>
<p>However, direct links between flavonoid-mediated p53 and the anti-oxidant Keap1/Nrf2/ARE pathway to exert preventive potentials are scarce. In contrast, many reports have shown a p53- mediated induction of cell death pathways that can be regulated by flavonoids in various cancer models. Further, exploring the role of flavonoids through the p53 pathway in disease prevention should be of great interest for future research. Understanding the safe and efficacious dose of flavonoids is also very crucial in treatment since most flavonoids, depending on the concentration and microenvironment, can act as either anti-oxidants or prooxidants exhibiting hormetic effects. Moreover, continuous efforts are in progress for enhancing the bioavailability of flavonoids by acylation to enhance cellular uptake, improving stability by using different formulations, engineering microbiota for their improved impacts, and developing technologies, such as nanocrystals, for enhanced pharmacokinetics and targeted therapy.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors thank the American University of Ras Al Khaimah (AURAK) for providing the infrastructure and facilities for the successful accomplishment of this project. <xref ref-type="fig" rid="biomedicines-08-00286-f001">Figure 1</xref>, <xref ref-type="fig" rid="biomedicines-08-00286-f002">Figure 2</xref>, and <xref ref-type="fig" rid="biomedicines-08-00286-f003">Figure 3</xref> were created with BioRender.com. The authors would like to thank Andrea Verhagen, Cellular and Molecular Medicine, University of California, San Diego, USA, for proofreading the article.</p>
</ack>
<notes>
<title>Funding</title>
<p>This work received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AID</td>
<td align="left" colspan="1" rowspan="1" valign="middle">activation-induced cytidine deaminase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AOM</td>
<td align="left" colspan="1" rowspan="1" valign="middle">azoxymethane</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AP1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">activator protein <italic>1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ARE</td>
<td align="left" colspan="1" rowspan="1" valign="middle">anti-oxidant response element</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ATP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">adenosine triphosphate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BSO</td>
<td align="left" colspan="1" rowspan="1" valign="middle">buthionine sulfoximine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cag-A</td>
<td align="left" colspan="1" rowspan="1" valign="middle">cytotoxin-associated gene A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cat</td>
<td align="left" colspan="1" rowspan="1" valign="middle">catalase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CIA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">collagen-induced arthritis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CNS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">central nervous system</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CVD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">cardiovascular diseases</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">DDR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">DNA damage <bold>r</bold>esponse</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">DMH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">1,2-dimethylhydrazine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">EAE</td>
<td align="left" colspan="1" rowspan="1" valign="middle">experimental autoimmune encephalomyelitis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">EGCG</td>
<td align="left" colspan="1" rowspan="1" valign="middle">epigallocatechin gallate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ERAP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">endoplasmic reticulum aminopeptidase 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HCC</td>
<td align="left" colspan="1" rowspan="1" valign="middle">hepatocellular carcinoma</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HFD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">high fat diet</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HIF1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">hypoxia inducible factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">IKK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">IκB kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">IPM</td>
<td align="left" colspan="1" rowspan="1" valign="middle">immune prognostic model</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LFS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Li-Fraumeni syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LOH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">loss of heterozygosity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">LPS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">lipopolysaccharides</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">M-CSF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">macrophage colony-stimulating factor </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MHC</td>
<td align="left" colspan="1" rowspan="1" valign="middle">major histocompatibility complex</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MMP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">matrix metalloprotease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NF-κB</td>
<td align="left" colspan="1" rowspan="1" valign="middle">nuclear factor-κB</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NRF2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">nuclear factor erythroid 2-related factor 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PAMPs</td>
<td align="left" colspan="1" rowspan="1" valign="middle">pathogen-associated molecular patterns</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PPAR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">peroxisome proliferator-activated receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PTEN</td>
<td align="left" colspan="1" rowspan="1" valign="middle">phosphatase and tensin homolog</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ROS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Reactive oxygen species</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SOCS1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">suppressors of cytokine signaling 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SOD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">superoxide dismutase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">STAT3</td>
<td align="left" colspan="1" rowspan="1" valign="middle">signal transducer and activator of transcription 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TAM</td>
<td align="left" colspan="1" rowspan="1" valign="middle">tumor-associated macrophage</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TAP1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">transporter associated with Antigen Processing 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TLR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">toll-like receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TNBS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">2,4,6-trinitrobenzenesulfonic acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">UVB</td>
<td align="left" colspan="1" rowspan="1" valign="middle">ultraviolet B radiation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">WT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">wild type</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-biomedicines-08-00286">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanahan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Hallmarks of cancer: The next generation</article-title>
<source/>Cell
          <year>2011</year>
<volume>144</volume>
<fpage>646</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
<pub-id pub-id-type="pmid">21376230</pub-id>
</element-citation>
</ref>
<ref id="B2-biomedicines-08-00286">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Bartek</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The DNA-damage response in human biology and disease</article-title>
<source/>Nature
          <year>2009</year>
<volume>461</volume>
<fpage>1071</fpage>
<lpage>1078</lpage>
<pub-id pub-id-type="doi">10.1038/nature08467</pub-id>
<pub-id pub-id-type="pmid">19847258</pub-id>
</element-citation>
</ref>
<ref id="B3-biomedicines-08-00286">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freed-Pastor</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Prives</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Mutant p53: One name, many proteins</article-title>
<source/>Genes Dev.
          <year>2012</year>
<volume>26</volume>
<fpage>1268</fpage>
<lpage>1286</lpage>
<pub-id pub-id-type="doi">10.1101/gad.190678.112</pub-id>
<pub-id pub-id-type="pmid">22713868</pub-id>
</element-citation>
</ref>
<ref id="B4-biomedicines-08-00286">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Oren</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The first 30 years of p53: Growing ever more complex</article-title>
<source/>Nat. Rev. Cancer
          <year>2009</year>
<volume>9</volume>
<fpage>749</fpage>
<lpage>758</lpage>
<pub-id pub-id-type="doi">10.1038/nrc2723</pub-id>
<pub-id pub-id-type="pmid">19776744</pub-id>
</element-citation>
</ref>
<ref id="B5-biomedicines-08-00286">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lane</surname>
<given-names>D.P.</given-names>
</name>
</person-group>
<article-title>Cancer. p53, guardian of the genome</article-title>
<source/>Nature
          <year>1992</year>
<volume>358</volume>
<fpage>15</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1038/358015a0</pub-id>
<pub-id pub-id-type="pmid">1614522</pub-id>
</element-citation>
</ref>
<ref id="B6-biomedicines-08-00286">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben David</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Prideaux</surname>
<given-names>V.R.</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Benchimol</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus</article-title>
<source/>Oncogene
          <year>1988</year>
<volume>3</volume>
<fpage>179</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="pmid">2842714</pub-id>
</element-citation>
</ref>
<ref id="B7-biomedicines-08-00286">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rotter</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences</article-title>
<source/>Mol. Cell. Biol.
          <year>1984</year>
<volume>4</volume>
<fpage>1402</fpage>
<lpage>1410</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.4.7.1402</pub-id>
<pub-id pub-id-type="pmid">6095069</pub-id>
</element-citation>
</ref>
<ref id="B8-biomedicines-08-00286">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Fearon</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Nigro</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Preisinger</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Jessup</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Van Tuinen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ledbetter</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas</article-title>
<source/>Science
          <year>1989</year>
<volume>244</volume>
<fpage>217</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1126/science.2649981</pub-id>
<pub-id pub-id-type="pmid">2649981</pub-id>
</element-citation>
</ref>
<ref id="B9-biomedicines-08-00286">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petitjean</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mathe</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ishioka</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tavtigian</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Hainaut</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database</article-title>
<source/>Hum. Mutat.
          <year>2007</year>
<volume>28</volume>
<fpage>622</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="doi">10.1002/humu.20495</pub-id>
<pub-id pub-id-type="pmid">17311302</pub-id>
</element-citation>
</ref>
<ref id="B10-biomedicines-08-00286">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donehower</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Slagle</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Butel</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title>
<source/>Nature
          <year>1992</year>
<volume>356</volume>
<fpage>215</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/356215a0</pub-id>
<pub-id pub-id-type="pmid">1552940</pub-id>
</element-citation>
</ref>
<ref id="B11-biomedicines-08-00286">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Fraumeni</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Rhabdomyosarcoma in children: Epidemiologic study and identification of a familial cancer syndrome</article-title>
<source/>J. Natl. Cancer Inst.
          <year>1969</year>
<volume>43</volume>
<fpage>1365</fpage>
<lpage>1373</lpage>
<pub-id pub-id-type="pmid">5396222</pub-id>
</element-citation>
</ref>
<ref id="B12-biomedicines-08-00286">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Fraumeni</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?</article-title>
<source/>Ann. Intern. Med.
          <year>1969</year>
<volume>71</volume>
<fpage>747</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="doi">10.7326/0003-4819-71-4-747</pub-id>
<pub-id pub-id-type="pmid">5360287</pub-id>
</element-citation>
</ref>
<ref id="B13-biomedicines-08-00286">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Z.Q.</given-names>
</name>
<name>
<surname>Pirollo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Blattner</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>E.H.</given-names>
</name>
</person-group>
<article-title>Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome</article-title>
<source/>Nature
          <year>1990</year>
<volume>348</volume>
<fpage>747</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.1038/348747a0</pub-id>
<pub-id pub-id-type="pmid">2259385</pub-id>
</element-citation>
</ref>
<ref id="B14-biomedicines-08-00286">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malkin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Fraumeni</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Kassel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gryka</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Bischoff</surname>
<given-names>F.Z.</given-names>
</name>
<name>
<surname>Tainsky</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms</article-title>
<source/>Science
          <year>1990</year>
<volume>250</volume>
<fpage>1233</fpage>
<lpage>1238</lpage>
<pub-id pub-id-type="doi">10.1126/science.1978757</pub-id>
<pub-id pub-id-type="pmid">1978757</pub-id>
</element-citation>
</ref>
<ref id="B15-biomedicines-08-00286">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fields</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>Presence of a potent transcription activating sequence in the p53 protein</article-title>
<source/>Science
          <year>1990</year>
<volume>249</volume>
<fpage>1046</fpage>
<lpage>1049</lpage>
<pub-id pub-id-type="doi">10.1126/science.2144363</pub-id>
<pub-id pub-id-type="pmid">2144363</pub-id>
</element-citation>
</ref>
<ref id="B16-biomedicines-08-00286">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sullivan</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Galbraith</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Andrysik</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Espinosa</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Mechanisms of transcriptional regulation by p53</article-title>
<source/>Cell Death Differ.
          <year>2018</year>
<volume>25</volume>
<fpage>133</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2017.174</pub-id>
<pub-id pub-id-type="pmid">29125602</pub-id>
</element-citation>
</ref>
<ref id="B17-biomedicines-08-00286">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raycroft</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene</article-title>
<source/>Science
          <year>1990</year>
<volume>249</volume>
<fpage>1049</fpage>
<lpage>1051</lpage>
<pub-id pub-id-type="doi">10.1126/science.2144364</pub-id>
<pub-id pub-id-type="pmid">2144364</pub-id>
</element-citation>
</ref>
<ref id="B18-biomedicines-08-00286">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nozawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kurumizaka</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Linker DNA and histone contributions in nucleosome binding by p53</article-title>
<source/>J. Biochem.
          <year>2020</year>
<fpage>mvva081</fpage>
<pub-id pub-id-type="doi">10.1093/jb/mvaa081</pub-id>
</element-citation>
</ref>
<ref id="B19-biomedicines-08-00286">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Characterization of porcine p53 and its regulation by porcine Mdm2</article-title>
<source/>Gene
          <year>2020</year>
<volume>748</volume>
<fpage>144699</fpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2020.144699</pub-id>
<pub-id pub-id-type="pmid">32334023</pub-id>
</element-citation>
</ref>
<ref id="B20-biomedicines-08-00286">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popova</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ladds</surname>
<given-names>M.J.G.W.</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Saleh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sandberg</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sahlberg</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gullberg</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability</article-title>
<source/>J. Med. Chem.
          <year>2020</year>
<volume>63</volume>
<fpage>3915</fpage>
<lpage>3934</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01658</pub-id>
<pub-id pub-id-type="pmid">32212728</pub-id>
</element-citation>
</ref>
<ref id="B21-biomedicines-08-00286">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurbegovic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Trudel</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease</article-title>
<source/>Cell. Signal.
          <year>2020</year>
<volume>71</volume>
<fpage>109594</fpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109594</pub-id>
<pub-id pub-id-type="pmid">32145315</pub-id>
</element-citation>
</ref>
<ref id="B22-biomedicines-08-00286">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sheikh</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>ECRG2, a novel transcriptional target of p53, modulates cancer cell sensitivity to DNA damage</article-title>
<source/>Cell Death Dis.
          <year>2020</year>
<volume>11</volume>
<fpage>543</fpage>
<pub-id pub-id-type="doi">10.1038/s41419-020-2728-1</pub-id>
<pub-id pub-id-type="pmid">32681017</pub-id>
</element-citation>
</ref>
<ref id="B23-biomedicines-08-00286">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puzio-Kuter</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>The Role of p53 in Metabolic Regulation</article-title>
<source/>Genes Cancer
          <year>2011</year>
<volume>2</volume>
<fpage>385</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="doi">10.1177/1947601911409738</pub-id>
<pub-id pub-id-type="pmid">21779507</pub-id>
</element-citation>
</ref>
<ref id="B24-biomedicines-08-00286">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muñoz-Fontela</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mandinova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aaronson</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Emerging roles of p53 and other tumour-suppressor genes in immune regulation</article-title>
<source/>Nat. Rev. Immunol.
          <year>2016</year>
<volume>16</volume>
<fpage>741</fpage>
<lpage>750</lpage>
<pub-id pub-id-type="doi">10.1038/nri.2016.99</pub-id>
<pub-id pub-id-type="pmid">27667712</pub-id>
</element-citation>
</ref>
<ref id="B25-biomedicines-08-00286">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandoth</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McLellan</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Vandin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>McMichael</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Wyczalkowski</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutational landscape and significance across 12 major cancer types</article-title>
<source/>Nature
          <year>2013</year>
<volume>502</volume>
<fpage>333</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="doi">10.1038/nature12634</pub-id>
<pub-id pub-id-type="pmid">24132290</pub-id>
</element-citation>
</ref>
<ref id="B26-biomedicines-08-00286">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kogan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carpizo</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Pharmacological targeting of mutant p53</article-title>
<source/>Transl. Cancer Res.
          <year>2016</year>
<volume>5</volume>
<fpage>698</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="doi">10.21037/tcr.2016.11.74</pub-id>
<pub-id pub-id-type="pmid">30956950</pub-id>
</element-citation>
</ref>
<ref id="B27-biomedicines-08-00286">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raghavan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Agrahari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gowda</surname>
<given-names>D.K.</given-names>
</name>
</person-group>
<article-title>Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics</article-title>
<source/>Comput. Biol. Chem.
          <year>2019</year>
<volume>80</volume>
<fpage>398</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1016/j.compbiolchem.2019.05.005</pub-id>
<pub-id pub-id-type="pmid">31128451</pub-id>
</element-citation>
</ref>
<ref id="B28-biomedicines-08-00286">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.-X.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.-X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.-M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.-B.</given-names>
</name>
</person-group>
<article-title>Virtual Screening Based on Ensemble Docking Targeting Wild-Type p53 for Anticancer Drug Discovery</article-title>
<source/>Chem. Biodivers.
          <year>2019</year>
<volume>16</volume>
<fpage>e1900170</fpage>
<pub-id pub-id-type="doi">10.1002/cbdv.201900170</pub-id>
<pub-id pub-id-type="pmid">31134745</pub-id>
</element-citation>
</ref>
<ref id="B29-biomedicines-08-00286">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Synnott</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klinger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Crown</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fersht</surname>
<given-names>A.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007</article-title>
<source/>Cancer Lett.
          <year>2018</year>
<volume>414</volume>
<fpage>99</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2017.09.053</pub-id>
<pub-id pub-id-type="pmid">29069577</pub-id>
</element-citation>
</ref>
<ref id="B30-biomedicines-08-00286">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Multhoff</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Molls</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Radons</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Chronic inflammation in cancer development</article-title>
<source/>Front. Immunol.
          <year>2011</year>
<volume>2</volume>
<fpage>98</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2011.00098</pub-id>
<pub-id pub-id-type="pmid">22566887</pub-id>
</element-citation>
</ref>
<ref id="B31-biomedicines-08-00286">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kruk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aboul-Enein</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>Reactive Oxygen and Nitrogen Species in Carcinogenesis: Implications of Oxidative Stress on the Progression and Development of Several Cancer Types</article-title>
<source/>Mini. Rev. Med. Chem.
          <year>2017</year>
<volume>17</volume>
<fpage>904</fpage>
<lpage>919</lpage>
<pub-id pub-id-type="doi">10.2174/1389557517666170228115324</pub-id>
<pub-id pub-id-type="pmid">28245782</pub-id>
</element-citation>
</ref>
<ref id="B32-biomedicines-08-00286">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Elsland</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Neefjes</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Bacterial infections and cancer</article-title>
<source/>EMBO Rep.
          <year>2018</year>
<volume>19</volume>
<fpage>e46632</fpage>
<pub-id pub-id-type="doi">10.15252/embr.201846632</pub-id>
<pub-id pub-id-type="pmid">30348892</pub-id>
</element-citation>
</ref>
<ref id="B33-biomedicines-08-00286">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uehara</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Role of p53 in the Regulation of the Inflammatory Tumor Microenvironment and Tumor Suppression</article-title>
<source/>Cancers
          <year>2018</year>
<volume>10</volume>
<elocation-id>219</elocation-id>
<pub-id pub-id-type="doi">10.3390/cancers10070219</pub-id>
<pub-id pub-id-type="pmid">29954119</pub-id>
</element-citation>
</ref>
<ref id="B34-biomedicines-08-00286">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okuda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>C.C.A.</given-names>
</name>
</person-group>
<article-title>Regulatory role of p53 in experimental autoimmune encephalomyelitis</article-title>
<source/>J. Neuroimmunol.
          <year>2003</year>
<volume>135</volume>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-5728(02)00428-9</pub-id>
<pub-id pub-id-type="pmid">12576221</pub-id>
</element-citation>
</ref>
<ref id="B35-biomedicines-08-00286">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamanishi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Pinkoski</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Mahboubi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zvaifler</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Firestein</surname>
<given-names>G.S.</given-names>
</name>
</person-group>
<article-title>Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis</article-title>
<source/>Am. J. Pathol.
          <year>2002</year>
<volume>160</volume>
<fpage>123</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)64356-8</pub-id>
<pub-id pub-id-type="pmid">11786406</pub-id>
</element-citation>
</ref>
<ref id="B36-biomedicines-08-00286">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Weeks</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Allred</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Chapkin</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Targeted Deletion of p53 in Lgr5-Expressing Intestinal Stem Cells Promotes Colon Tumorigenesis in a Preclinical Model of Colitis-Associated Cancer</article-title>
<source/>Cancer Res.
          <year>2015</year>
<volume>75</volume>
<fpage>5392</fpage>
<lpage>5397</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1706</pub-id>
<pub-id pub-id-type="pmid">26631266</pub-id>
</element-citation>
</ref>
<ref id="B37-biomedicines-08-00286">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawauchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tobiume</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Activated p53 induces NF-kappaB DNA binding but suppresses its transcriptional activation</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2008</year>
<volume>372</volume>
<fpage>137</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2008.05.021</pub-id>
<pub-id pub-id-type="pmid">18477470</pub-id>
</element-citation>
</ref>
<ref id="B38-biomedicines-08-00286">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Son</surname>
<given-names>D.-S.</given-names>
</name>
<name>
<surname>Kabir</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Adunyah</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<elocation-id>e51116</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0051116</pub-id>
<pub-id pub-id-type="pmid">23300534</pub-id>
</element-citation>
</ref>
<ref id="B39-biomedicines-08-00286">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blagih</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Buck</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Vousden</surname>
<given-names>K.H.</given-names>
</name>
</person-group>
<article-title>P53, cancer and the immune response</article-title>
<source/>J. Cell. Sci.
          <year>2020</year>
<volume>133</volume>
<fpage>jcs237453</fpage>
<pub-id pub-id-type="doi">10.1242/jcs.237453</pub-id>
<pub-id pub-id-type="pmid">32144194</pub-id>
</element-citation>
</ref>
<ref id="B40-biomedicines-08-00286">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keates</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hitti</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Upton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>C.P.</given-names>
</name>
</person-group>
<article-title>Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells</article-title>
<source/>Gastroenterology
          <year>1997</year>
<volume>113</volume>
<fpage>1099</fpage>
<lpage>1109</lpage>
<pub-id pub-id-type="doi">10.1053/gast.1997.v113.pm9322504</pub-id>
<pub-id pub-id-type="pmid">9322504</pub-id>
</element-citation>
</ref>
<ref id="B41-biomedicines-08-00286">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uemura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matsumura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamakido</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Taniyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schlemper</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Helicobacter pylori infection and the development of gastric cancer</article-title>
<source/>N. Engl. J. Med.
          <year>2001</year>
<volume>345</volume>
<fpage>784</fpage>
<lpage>789</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa001999</pub-id>
<pub-id pub-id-type="pmid">11556297</pub-id>
</element-citation>
</ref>
<ref id="B42-biomedicines-08-00286">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Marusawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Morisawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Azuma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Okazaki</surname>
<given-names>I.-M.</given-names>
</name>
<name>
<surname>Honjo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium</article-title>
<source/>Nat. Med.
          <year>2007</year>
<volume>13</volume>
<fpage>470</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="doi">10.1038/nm1566</pub-id>
<pub-id pub-id-type="pmid">17401375</pub-id>
</element-citation>
</ref>
<ref id="B43-biomedicines-08-00286">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butin-Israeli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bui</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Wiesolek</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Mascarenhas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Mehl</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Knutson</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Beyder</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing</article-title>
<source/>J. Clin. Invest.
          <year>2019</year>
<volume>129</volume>
<fpage>712</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1172/JCI122085</pub-id>
<pub-id pub-id-type="pmid">30640176</pub-id>
</element-citation>
</ref>
<ref id="B44-biomedicines-08-00286">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brazil</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Parkos</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease</article-title>
<source/>Inflamm. Bowel Dis.
          <year>2013</year>
<volume>19</volume>
<fpage>1556</fpage>
<lpage>1565</lpage>
<pub-id pub-id-type="doi">10.1097/MIB.0b013e318281f54e</pub-id>
<pub-id pub-id-type="pmid">23598816</pub-id>
</element-citation>
</ref>
<ref id="B45-biomedicines-08-00286">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieczorek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abualrous</surname>
<given-names>E.T.</given-names>
</name>
<name>
<surname>Sticht</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Álvaro-Benito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stolzenberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Noé</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Freund</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation</article-title>
<source/>Front. Immunol.
          <year>2017</year>
<volume>8</volume>
<fpage>292</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.00292</pub-id>
<pub-id pub-id-type="pmid">28367149</pub-id>
</element-citation>
</ref>
<ref id="B46-biomedicines-08-00286">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffioen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Steegenga</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Ouwerkerk</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Peltenburg</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Jochemsen</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Schrier</surname>
<given-names>P.I.</given-names>
</name>
</person-group>
<article-title>Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms</article-title>
<source/>Mol. Immunol.
          <year>1998</year>
<volume>35</volume>
<fpage>829</fpage>
<lpage>835</lpage>
<pub-id pub-id-type="doi">10.1016/S0161-5890(98)00074-1</pub-id>
<pub-id pub-id-type="pmid">9839551</pub-id>
</element-citation>
</ref>
<ref id="B47-biomedicines-08-00286">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<article-title>P53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1</article-title>
<source/>Nat. Commun.
          <year>2013</year>
<volume>4</volume>
<fpage>2359</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms3359</pub-id>
<pub-id pub-id-type="pmid">23965983</pub-id>
</element-citation>
</ref>
<ref id="B48-biomedicines-08-00286">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>P53 induces TAP1 and enhances the transport of MHC class I peptides</article-title>
<source/>Oncogene
          <year>1999</year>
<volume>18</volume>
<fpage>7740</fpage>
<lpage>7747</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1203235</pub-id>
<pub-id pub-id-type="pmid">10618714</pub-id>
</element-citation>
</ref>
<ref id="B49-biomedicines-08-00286">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garancher</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Haricharan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chau</surname>
<given-names>L.Q.</given-names>
</name>
<name>
<surname>Masihi</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Rusert</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Norris</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Carrette</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Morrissy</surname>
<given-names>S.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma</article-title>
<source/>Nat. Neurosci.
          <year>2020</year>
<volume>23</volume>
<fpage>842</fpage>
<lpage>853</lpage>
<pub-id pub-id-type="doi">10.1038/s41593-020-0628-4</pub-id>
<pub-id pub-id-type="pmid">32424282</pub-id>
</element-citation>
</ref>
<ref id="B50-biomedicines-08-00286">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharpe</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Pauken</surname>
<given-names>K.E.</given-names>
</name>
</person-group>
<article-title>The diverse functions of the PD1 inhibitory pathway</article-title>
<source/>Nat. Rev. Immunol.
          <year>2018</year>
<volume>18</volume>
<fpage>153</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.1038/nri.2017.108</pub-id>
<pub-id pub-id-type="pmid">28990585</pub-id>
</element-citation>
</ref>
<ref id="B51-biomedicines-08-00286">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Iwai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bourque</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chernova</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fitz</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Malenkovich</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Okazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>M.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</article-title>
<source/>J. Exp. Med.
          <year>2000</year>
<volume>192</volume>
<fpage>1027</fpage>
<lpage>1034</lpage>
<pub-id pub-id-type="doi">10.1084/jem.192.7.1027</pub-id>
<pub-id pub-id-type="pmid">11015443</pub-id>
</element-citation>
</ref>
<ref id="B52-biomedicines-08-00286">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortez</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Ivan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Valdecanas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Peltier</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Araujo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Shilo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Giri</surname>
<given-names>D.K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PDL1 Regulation by p53 via miR-34</article-title>
<source/>J. Natl. Cancer Inst.
          <year>2016</year>
<volume>108</volume>
<fpage>djv303</fpage>
<pub-id pub-id-type="doi">10.1093/jnci/djv303</pub-id>
<pub-id pub-id-type="pmid">26577528</pub-id>
</element-citation>
</ref>
<ref id="B53-biomedicines-08-00286">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hatae</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Honjo</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Current issues and perspectives in PD-1 blockade cancer immunotherapy</article-title>
<source/>Int. J. Clin. Oncol.
          <year>2020</year>
<volume>25</volume>
<fpage>790</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="doi">10.1007/s10147-019-01588-7</pub-id>
<pub-id pub-id-type="pmid">31900651</pub-id>
</element-citation>
</ref>
<ref id="B54-biomedicines-08-00286">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nie</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>J.-Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Toll-Like Receptors, Associated Biological Roles, and Signaling Networks in Non-Mammals</article-title>
<source/>Front. Immunol.
          <year>2018</year>
<volume>9</volume>
<fpage>1523</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2018.01523</pub-id>
<pub-id pub-id-type="pmid">30034391</pub-id>
</element-citation>
</ref>
<ref id="B55-biomedicines-08-00286">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urban-Wojciuk</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Oyler</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Fåhraeus</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Marek-Trzonkowska</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nita-Lazar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hupp</surname>
<given-names>T.R.</given-names>
</name>
<name>
<surname>Goodlett</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>The Role of TLRs in Anti-cancer Immunity and Tumor Rejection</article-title>
<source/>Front. Immunol.
          <year>2019</year>
<volume>10</volume>
<fpage>2388</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.02388</pub-id>
<pub-id pub-id-type="pmid">31695691</pub-id>
</element-citation>
</ref>
<ref id="B56-biomedicines-08-00286">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menendez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Snipe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Resnick</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>61630</fpage>
<lpage>61642</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.11210</pub-id>
<pub-id pub-id-type="pmid">27533082</pub-id>
</element-citation>
</ref>
<ref id="B57-biomedicines-08-00286">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shatz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shats</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Menendez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Resnick</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>P53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>16963</fpage>
<lpage>16980</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.4435</pub-id>
<pub-id pub-id-type="pmid">26220208</pub-id>
</element-citation>
</ref>
<ref id="B58-biomedicines-08-00286">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haricharan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2015</year>
<volume>112</volume>
<fpage>E3216</fpage>
<lpage>E3225</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1420811112</pub-id>
<pub-id pub-id-type="pmid">26063617</pub-id>
</element-citation>
</ref>
<ref id="B59-biomedicines-08-00286">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menendez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Snipe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marzec</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Innes</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Polack</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Caballero</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Schurman</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Kleeberger</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Resnick</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>P53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus</article-title>
<source/>J. Clin. Invest.
          <year>2019</year>
<volume>129</volume>
<fpage>4875</fpage>
<lpage>4884</lpage>
<pub-id pub-id-type="doi">10.1172/JCI128626</pub-id>
<pub-id pub-id-type="pmid">31430261</pub-id>
</element-citation>
</ref>
<ref id="B60-biomedicines-08-00286">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rusanen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marttila</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Uittamo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hagström</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Salo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rautemaa-Richardson</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>TLR1-10, NF-κB and p53 expression is increased in oral lichenoid disease</article-title>
<source/>PLoS ONE
          <year>2017</year>
<volume>12</volume>
<elocation-id>e0181361</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0181361</pub-id>
<pub-id pub-id-type="pmid">28715461</pub-id>
</element-citation>
</ref>
<ref id="B61-biomedicines-08-00286">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Quan</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Palmitate induces VSMC apoptosis via toll like receptor (TLR)4/ROS/p53 pathway</article-title>
<source/>Atherosclerosis
          <year>2017</year>
<volume>263</volume>
<fpage>74</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2017.06.002</pub-id>
<pub-id pub-id-type="pmid">28609685</pub-id>
</element-citation>
</ref>
<ref id="B62-biomedicines-08-00286">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>S.-W.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>S.-W.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.-T.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>J.-K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.-J.</given-names>
</name>
<name>
<surname>Shieh</surname>
<given-names>J.-J.</given-names>
</name>
</person-group>
<article-title>Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line</article-title>
<source/>J. Dermatol. Sci.
          <year>2016</year>
<volume>81</volume>
<fpage>182</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/j.jdermsci.2015.12.011</pub-id>
<pub-id pub-id-type="pmid">26775629</pub-id>
</element-citation>
</ref>
<ref id="B63-biomedicines-08-00286">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wellenstein</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Coffelt</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Duits</surname>
<given-names>D.E.M.</given-names>
</name>
<name>
<surname>Van Miltenburg</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Slagter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Rink</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Henneman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kas</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Prekovic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hau</surname>
<given-names>C.-S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis</article-title>
<source/>Nature
          <year>2019</year>
<volume>572</volume>
<fpage>538</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-019-1450-6</pub-id>
<pub-id pub-id-type="pmid">31367040</pub-id>
</element-citation>
</ref>
<ref id="B64-biomedicines-08-00286">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bezzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Seitzer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Reschke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Katon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lunardi</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms</article-title>
<source/>Nat. Med.
          <year>2018</year>
<volume>24</volume>
<fpage>165</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1038/nm.4463</pub-id>
<pub-id pub-id-type="pmid">29309058</pub-id>
</element-citation>
</ref>
<ref id="B65-biomedicines-08-00286">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walton</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Blagih</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ennis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dowson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Farquharson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tookman</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Orange</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Athineos</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma</article-title>
<source/>Cancer Res.
          <year>2016</year>
<volume>76</volume>
<fpage>6118</fpage>
<lpage>6129</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1272</pub-id>
<pub-id pub-id-type="pmid">27530326</pub-id>
</element-citation>
</ref>
<ref id="B66-biomedicines-08-00286">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruddell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kelly-Spratt</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Furuya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parghi</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>P19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis</article-title>
<source/>Oncogene
          <year>2008</year>
<volume>27</volume>
<fpage>3145</fpage>
<lpage>3155</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1210973</pub-id>
<pub-id pub-id-type="pmid">18059331</pub-id>
</element-citation>
</ref>
<ref id="B67-biomedicines-08-00286">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blagih</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chakravarty</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hennequart</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pilley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hobor</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hock</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Gronroos</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses</article-title>
<source/>Cell Rep.
          <year>2020</year>
<volume>30</volume>
<fpage>481</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2019.12.028</pub-id>
<pub-id pub-id-type="pmid">31940491</pub-id>
</element-citation>
</ref>
<ref id="B68-biomedicines-08-00286">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bentley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wiblin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cleary</surname>
<given-names>K.L.S.</given-names>
</name>
<name>
<surname>Koustoulidou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hassanali</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Greig</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nordkamp</surname>
<given-names>M.O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy</article-title>
<source/>Cancer Res.
          <year>2017</year>
<volume>77</volume>
<fpage>2699</fpage>
<lpage>2711</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-3247</pub-id>
<pub-id pub-id-type="pmid">28363997</pub-id>
</element-citation>
</ref>
<ref id="B69-biomedicines-08-00286">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Low</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.-I.</given-names>
</name>
</person-group>
<article-title>Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen</article-title>
<source/>Nat. Commun.
          <year>2019</year>
<volume>10</volume>
<fpage>5382</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-019-13305-z</pub-id>
<pub-id pub-id-type="pmid">31772160</pub-id>
</element-citation>
</ref>
<ref id="B70-biomedicines-08-00286">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kortylewski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Stat3 as a Potential Target for Cancer Immunotherapy</article-title>
<source/>J. Immunother.
          <year>2007</year>
<volume>30</volume>
<fpage>131</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1097/01.cji.0000211327.76266.65</pub-id>
<pub-id pub-id-type="pmid">17471161</pub-id>
</element-citation>
</ref>
<ref id="B71-biomedicines-08-00286">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wörmann</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Diakopoulos</surname>
<given-names>K.N.</given-names>
</name>
<name>
<surname>Kurkowski</surname>
<given-names>M.U.</given-names>
</name>
<name>
<surname>Görgülü</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ruess</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Doglioni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jodrell</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival</article-title>
<source/>Gastroenterology
          <year>2016</year>
<volume>151</volume>
<fpage>180</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2016.03.010</pub-id>
<pub-id pub-id-type="pmid">27003603</pub-id>
</element-citation>
</ref>
<ref id="B72-biomedicines-08-00286">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nowak</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Herzka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Watrud</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>DeMarco</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>V.M.Y.</given-names>
</name>
<name>
<surname>Senturk</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fellmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Beinortas</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2</article-title>
<source/>Cancer Discov.
          <year>2015</year>
<volume>5</volume>
<fpage>636</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-1113</pub-id>
<pub-id pub-id-type="pmid">25829425</pub-id>
</element-citation>
</ref>
<ref id="B73-biomedicines-08-00286">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mallette</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Deschênes-Simard</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ramanathan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moores</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ilangumaran</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferbeyre</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>SOCS1 links cytokine signaling to p53 and senescence</article-title>
<source/>Mol. Cell
          <year>2009</year>
<volume>36</volume>
<fpage>754</fpage>
<lpage>767</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2009.09.044</pub-id>
<pub-id pub-id-type="pmid">20005840</pub-id>
</element-citation>
</ref>
<ref id="B74-biomedicines-08-00286">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooks</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pateras</surname>
<given-names>I.S.</given-names>
</name>
<name>
<surname>Tarcic</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schetter</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Wilder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pikarsky</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Forshew</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer</article-title>
<source/>Cancer Cell
          <year>2013</year>
<volume>23</volume>
<fpage>634</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.1016/j.ccr.2013.03.022</pub-id>
<pub-id pub-id-type="pmid">23680148</pub-id>
</element-citation>
</ref>
<ref id="B75-biomedicines-08-00286">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahnamoun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Duttke</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Benner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Lauberth</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling</article-title>
<source/>Nat. Commun.
          <year>2017</year>
<volume>8</volume>
<fpage>754</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-017-01117-y</pub-id>
<pub-id pub-id-type="pmid">28963538</pub-id>
</element-citation>
</ref>
<ref id="B76-biomedicines-08-00286">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ubertini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Norelli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>D’Arcangelo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gurtner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cesareo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Baldari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gentileschi</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Piaggio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nisticò</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Soddu</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist</article-title>
<source/>Oncogene
          <year>2015</year>
<volume>34</volume>
<fpage>2493</fpage>
<lpage>2504</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2014.191</pub-id>
<pub-id pub-id-type="pmid">24998848</pub-id>
</element-citation>
</ref>
<ref id="B77-biomedicines-08-00286">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Headland</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Norling</surname>
<given-names>L.V.</given-names>
</name>
</person-group>
<article-title>The resolution of inflammation: Principles and challenges</article-title>
<source/>Semin. Immunol.
          <year>2015</year>
<volume>27</volume>
<fpage>149</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.1016/j.smim.2015.03.014</pub-id>
<pub-id pub-id-type="pmid">25911383</pub-id>
</element-citation>
</ref>
<ref id="B78-biomedicines-08-00286">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Baby</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rajguru</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thakkannavar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pujari</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Inflammation and cancer</article-title>
<source/>Ann. Afr. Med.
          <year>2019</year>
<volume>18</volume>
<fpage>121</fpage>
<pub-id pub-id-type="doi">10.4103/aam.aam_56_18</pub-id>
<pub-id pub-id-type="pmid">31417011</pub-id>
</element-citation>
</ref>
<ref id="B79-biomedicines-08-00286">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nathan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Nonresolving Inflammation</article-title>
<source/>Cell
          <year>2010</year>
<volume>140</volume>
<fpage>871</fpage>
<lpage>882</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2010.02.029</pub-id>
<pub-id pub-id-type="pmid">20303877</pub-id>
</element-citation>
</ref>
<ref id="B80-biomedicines-08-00286">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Inflammatory responses and inflammation-associated diseases in organs</article-title>
<source/>Oncotarget
          <year>2018</year>
<volume>9</volume>
<fpage>7204</fpage>
<lpage>7218</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.23208</pub-id>
<pub-id pub-id-type="pmid">29467962</pub-id>
</element-citation>
</ref>
<ref id="B81-biomedicines-08-00286">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamp</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Shacter</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Weitzman</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Chronic inflammation and cancer: The role of the mitochondria</article-title>
<source/>Oncology (Williston Park, N.Y.)
          <year>2011</year>
<volume>25</volume>
<fpage>400</fpage>
<lpage>413</lpage>
<page-range>400–410, 413</page-range>
</element-citation>
</ref>
<ref id="B82-biomedicines-08-00286">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Akaike</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Nitric oxide and oxygen radicals in infection, inflammation, and cancer</article-title>
<source/>Biochem. Mosc.
          <year>1998</year>
<volume>63</volume>
<fpage>854</fpage>
<lpage>865</lpage>
</element-citation>
</ref>
<ref id="B83-biomedicines-08-00286">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawanishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hiraku</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oikawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells</article-title>
<source/>Genes Environ.
          <year>2016</year>
<volume>38</volume>
<fpage>26</fpage>
<pub-id pub-id-type="doi">10.1186/s41021-016-0055-7</pub-id>
<pub-id pub-id-type="pmid">28050219</pub-id>
</element-citation>
</ref>
<ref id="B84-biomedicines-08-00286">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Souici</surname>
<given-names>A.-C.</given-names>
</name>
</person-group>
<article-title>Transition mutation in codon 248 of the p53 tumor suppressor gene induced by reactive oxygen species and a nitric oxide-releasing compound</article-title>
<source/>Carcinogenesis
          <year>2000</year>
<volume>21</volume>
<fpage>281</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/21.2.281</pub-id>
<pub-id pub-id-type="pmid">10657969</pub-id>
</element-citation>
</ref>
<ref id="B85-biomedicines-08-00286">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coussens</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Werb</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Inflammation and cancer</article-title>
<source/>Nature
          <year>2002</year>
<volume>420</volume>
<fpage>860</fpage>
<lpage>867</lpage>
<pub-id pub-id-type="doi">10.1038/nature01322</pub-id>
<pub-id pub-id-type="pmid">12490959</pub-id>
</element-citation>
</ref>
<ref id="B86-biomedicines-08-00286">
<label>86.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Varki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schnaar</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Crocker</surname>
<given-names>P.R.</given-names>
</name>
</person-group>
<article-title>I-Type Lectins</article-title>
<source/>Essentials of Glycobiology
          <person-group person-group-type="editor">
<name>
<surname>Varki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Esko</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Stanley</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Aebi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Darvill</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Packer</surname>
<given-names>N.H.</given-names>
</name>
<name>
<surname>Prestegard</surname>
<given-names>J.H.</given-names>
</name>
<etal></etal>
</person-group>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
<publisher-loc>Cold Spring Harbor, NY, USA</publisher-loc>
<year>2015</year>
</element-citation>
</ref>
<ref id="B87-biomedicines-08-00286">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siddiqui</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Matar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Merheb</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hodeify</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vazhappilly</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Marton</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shamsuddin</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Al Zouabi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Siglecs in Brain Function and Neurological Disorders</article-title>
<source/>Cells
          <year>2019</year>
<volume>8</volume>
<elocation-id>1125</elocation-id>
<pub-id pub-id-type="doi">10.3390/cells8101125</pub-id>
</element-citation>
</ref>
<ref id="B88-biomedicines-08-00286">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siddiqui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Springer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khedri</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Verhagen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Naito-Matsui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E</article-title>
<source/>J. Biol. Chem.
          <year>2017</year>
<volume>292</volume>
<fpage>1029</fpage>
<lpage>1037</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M116.738351</pub-id>
<pub-id pub-id-type="pmid">27920204</pub-id>
</element-citation>
</ref>
<ref id="B89-biomedicines-08-00286">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siddiqui</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Springer</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Verhagen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sundaramurthy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Alisson-Silva</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Varki</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The Alzheimer’s disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool</article-title>
<source/>J. Biol. Chem.
          <year>2017</year>
<volume>292</volume>
<fpage>15312</fpage>
<lpage>15320</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M117.799346</pub-id>
<pub-id pub-id-type="pmid">28747436</pub-id>
</element-citation>
</ref>
<ref id="B90-biomedicines-08-00286">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Läubli</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>O.M.T.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stanczak</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Verhagen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Secrest</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lusk</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2014</year>
<volume>111</volume>
<fpage>14211</fpage>
<lpage>14216</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1409580111</pub-id>
<pub-id pub-id-type="pmid">25225409</pub-id>
</element-citation>
</ref>
<ref id="B91-biomedicines-08-00286">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Läubli</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Alisson-Silva</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Stanczak</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Verhagen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Varki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Varki</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs</article-title>
<source/>J. Biol. Chem.
          <year>2014</year>
<volume>289</volume>
<fpage>33481</fpage>
<lpage>33491</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M114.593129</pub-id>
<pub-id pub-id-type="pmid">25320078</pub-id>
</element-citation>
</ref>
<ref id="B92-biomedicines-08-00286">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanczak</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Trefny</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Thommen</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Boligan</surname>
<given-names>K.F.</given-names>
</name>
<name>
<surname>Von Gunten</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tzankov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tietze</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lardinois</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Heinzelmann-Schwarz</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells</article-title>
<source/>J. Clin. Invest.
          <year>2018</year>
<volume>128</volume>
<fpage>4912</fpage>
<lpage>4923</lpage>
<pub-id pub-id-type="doi">10.1172/JCI120612</pub-id>
<pub-id pub-id-type="pmid">30130255</pub-id>
</element-citation>
</ref>
<ref id="B93-biomedicines-08-00286">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uchiyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fukahori</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Varki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marth</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Nizet</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Dual actions of group B Streptococcus capsular sialic acid provide resistance to platelet-mediated antimicrobial killing</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2019</year>
<volume>116</volume>
<fpage>7465</fpage>
<lpage>7470</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1815572116</pub-id>
<pub-id pub-id-type="pmid">30910970</pub-id>
</element-citation>
</ref>
<ref id="B94-biomedicines-08-00286">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Verhagen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Springer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Varki</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Controversies about the subcellular localization and mechanisms of action of the Alzheimer’s disease-protective CD33 splice variant</article-title>
<source/>Acta Neuropathol.
          <year>2019</year>
<volume>138</volume>
<fpage>671</fpage>
<lpage>672</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-019-02065-1</pub-id>
<pub-id pub-id-type="pmid">31440824</pub-id>
</element-citation>
</ref>
<ref id="B95-biomedicines-08-00286">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Landig</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Secundino</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Varki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nizet</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Varki</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Paired Siglec receptors generate opposite inflammatory responses to a human-specific pathogen</article-title>
<source/>EMBO J.
          <year>2017</year>
<volume>36</volume>
<fpage>751</fpage>
<lpage>760</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201695581</pub-id>
<pub-id pub-id-type="pmid">28100677</pub-id>
</element-citation>
</ref>
<ref id="B96-biomedicines-08-00286">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De la Vega</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>NRF2 and the Hallmarks of Cancer</article-title>
<source/>Cancer Cell
          <year>2018</year>
<volume>34</volume>
<fpage>21</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.022</pub-id>
<pub-id pub-id-type="pmid">29731393</pub-id>
</element-citation>
</ref>
<ref id="B97-biomedicines-08-00286">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Nrf2 in cancers: A double-edged sword</article-title>
<source/>Cancer Med.
          <year>2019</year>
<volume>8</volume>
<fpage>2252</fpage>
<lpage>2267</lpage>
<pub-id pub-id-type="doi">10.1002/cam4.2101</pub-id>
<pub-id pub-id-type="pmid">30929309</pub-id>
</element-citation>
</ref>
<ref id="B98-biomedicines-08-00286">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>S.M.U.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Namani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Nrf2 signaling pathway: Pivotal roles in inflammation</article-title>
<source/>Biochim. et Biophys. Acta (BBA) Mol. Basis Dis.
          <year>2017</year>
<volume>1863</volume>
<fpage>585</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2016.11.005</pub-id>
</element-citation>
</ref>
<ref id="B99-biomedicines-08-00286">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sha</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The Anti-Inflammatory and Anti-Oxidant Mechanisms of the Keap1/Nrf2/ARE Signaling Pathway in Chronic Diseases</article-title>
<source/>Aging Dis.
          <year>2019</year>
<volume>10</volume>
<fpage>637</fpage>
<pub-id pub-id-type="doi">10.14336/AD.2018.0513</pub-id>
<pub-id pub-id-type="pmid">31165007</pub-id>
</element-citation>
</ref>
<ref id="B100-biomedicines-08-00286">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.-J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response</article-title>
<source/>Mol. Cell
          <year>2009</year>
<volume>34</volume>
<fpage>663</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2009.04.029</pub-id>
<pub-id pub-id-type="pmid">19560419</pub-id>
</element-citation>
</ref>
<ref id="B101-biomedicines-08-00286">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimta</surname>
<given-names>A.-A.</given-names>
</name>
<name>
<surname>Cenariu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Irimie</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Magdo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nabavi</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Atanasov</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Berindan-Neagoe</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>The Role of Nrf2 Activity in Cancer Development and Progression</article-title>
<source/>Cancers
          <year>2019</year>
<volume>11</volume>
<elocation-id>1755</elocation-id>
<pub-id pub-id-type="doi">10.3390/cancers11111755</pub-id>
</element-citation>
</ref>
<ref id="B102-biomedicines-08-00286">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menegon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Columbano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The Dual Roles of NRF2 in Cancer</article-title>
<source/>Trends Mol. Med.
          <year>2016</year>
<volume>22</volume>
<fpage>578</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2016.05.002</pub-id>
<pub-id pub-id-type="pmid">27263465</pub-id>
</element-citation>
</ref>
<ref id="B103-biomedicines-08-00286">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaramillo</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>The emerging role of the Nrf2-Keap1 signaling pathway in cancer</article-title>
<source/>Genes Dev.
          <year>2013</year>
<volume>27</volume>
<fpage>2179</fpage>
<lpage>2191</lpage>
<pub-id pub-id-type="doi">10.1101/gad.225680.113</pub-id>
<pub-id pub-id-type="pmid">24142871</pub-id>
</element-citation>
</ref>
<ref id="B104-biomedicines-08-00286">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussain</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Blachier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tossou</surname>
<given-names>M.C.B.</given-names>
</name>
<name>
<surname>Rahu</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Oxidative Stress and Inflammation: What Polyphenols Can Do for Us?</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2016</year>
<volume>2016</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1155/2016/7432797</pub-id>
<pub-id pub-id-type="pmid">27738491</pub-id>
</element-citation>
</ref>
<ref id="B105-biomedicines-08-00286">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redza-Dutordoir</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Averill-Bates</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Activation of apoptosis signalling pathways by reactive oxygen species</article-title>
<source/>Biochim. et Biophys. Acta (BBA) Mol. Cell Res.
          <year>2016</year>
<volume>1863</volume>
<fpage>2977</fpage>
<lpage>2992</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.09.012</pub-id>
<pub-id pub-id-type="pmid">27646922</pub-id>
</element-citation>
</ref>
<ref id="B106-biomedicines-08-00286">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Muhammad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The immune-adjuvant activity and the mechanism of resveratrol on pseudorabies virus vaccine in a mouse model</article-title>
<source/>Int. Immunopharmacol.
          <year>2019</year>
<volume>76</volume>
<fpage>105876</fpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2019.105876</pub-id>
<pub-id pub-id-type="pmid">31499271</pub-id>
</element-citation>
</ref>
<ref id="B107-biomedicines-08-00286">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Lycopene alleviates H<sub>2</sub>O<sub>2</sub>-induced oxidative stress, inflammation and apoptosis in bovine mammary epithelial cells via the NFE2L2 signaling pathway</article-title>
<source/>Food Funct.
          <year>2019</year>
<volume>10</volume>
<fpage>6276</fpage>
<lpage>6285</lpage>
<pub-id pub-id-type="doi">10.1039/C9FO01922G</pub-id>
<pub-id pub-id-type="pmid">31576860</pub-id>
</element-citation>
</ref>
<ref id="B108-biomedicines-08-00286">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nadeem</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Al-Harbi</surname>
<given-names>N.O.</given-names>
</name>
<name>
<surname>Attia</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Alshammari</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Alzahrani</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Bakheet</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Increased oxidative stress in the cerebellum and peripheral immune cells leads to exaggerated autism-like repetitive behavior due to deficiency of antioxidant response in BTBR T + tf/J mice</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2019</year>
<volume>89</volume>
<fpage>245</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2018.09.012</pub-id>
<pub-id pub-id-type="pmid">30261217</pub-id>
</element-citation>
</ref>
<ref id="B109-biomedicines-08-00286">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solleiro-Villavicencio</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rivas-Arancibia</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Effect of Chronic Oxidative Stress on Neuroinflammatory Response Mediated by CD4+T Cells in Neurodegenerative Diseases</article-title>
<source/>Front. Cell. Neurosci.
          <year>2018</year>
<volume>12</volume>
<fpage>114</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2018.00114</pub-id>
<pub-id pub-id-type="pmid">29755324</pub-id>
</element-citation>
</ref>
<ref id="B110-biomedicines-08-00286">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>NF-B as a Critical Link Between Inflammation and Cancer</article-title>
<source/>Cold Spring Harb. Perspect. Biol.
          <year>2009</year>
<volume>1</volume>
<fpage>a000141</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a000141</pub-id>
<pub-id pub-id-type="pmid">20066113</pub-id>
</element-citation>
</ref>
<ref id="B111-biomedicines-08-00286">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plewka</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Plewka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miskiewicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bogunia</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Nuclear factor-kappa B as potential therapeutic target in human colon cancer</article-title>
<source/>J. Cancer Res. Ther.
          <year>2018</year>
<volume>14</volume>
<fpage>516</fpage>
<pub-id pub-id-type="doi">10.4103/0973-1482.180607</pub-id>
<pub-id pub-id-type="pmid">29893308</pub-id>
</element-citation>
</ref>
<ref id="B112-biomedicines-08-00286">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression</article-title>
<source/>Cold Spring Harb. Perspect. Med.
          <year>2016</year>
<volume>6</volume>
<fpage>a026104</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a026104</pub-id>
<pub-id pub-id-type="pmid">26931810</pub-id>
</element-citation>
</ref>
<ref id="B113-biomedicines-08-00286">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Butera</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pacchiana</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Masetto</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mullappilly</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Riganti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Donadelli</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells</article-title>
<source/>Biomolecules
          <year>2020</year>
<volume>10</volume>
<elocation-id>361</elocation-id>
<pub-id pub-id-type="doi">10.3390/biom10030361</pub-id>
<pub-id pub-id-type="pmid">32111081</pub-id>
</element-citation>
</ref>
<ref id="B114-biomedicines-08-00286">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The tango of ROS and p53 in tissue stem cells</article-title>
<source/>Cell Death Differ.
          <year>2018</year>
<volume>25</volume>
<fpage>639</fpage>
<lpage>641</lpage>
<pub-id pub-id-type="doi">10.1038/s41418-018-0062-2</pub-id>
<pub-id pub-id-type="pmid">29487352</pub-id>
</element-citation>
</ref>
<ref id="B115-biomedicines-08-00286">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olivos</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mayo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Emerging Non-Canonical Functions and Regulation by p53: P53 and Stemness</article-title>
<source/>Int. J. Mol. Sci.
          <year>2016</year>
<volume>17</volume>
<elocation-id>1982</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms17121982</pub-id>
<pub-id pub-id-type="pmid">27898034</pub-id>
</element-citation>
</ref>
<ref id="B116-biomedicines-08-00286">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Chaturvedi</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>B.B.</given-names>
</name>
</person-group>
<article-title>Oxidative stress, inflammation, and cancer: How are they linked?</article-title>
<source/>Free Radic. Biol. Med.
          <year>2010</year>
<volume>49</volume>
<fpage>1603</fpage>
<lpage>1616</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.09.006</pub-id>
<pub-id pub-id-type="pmid">20840865</pub-id>
</element-citation>
</ref>
<ref id="B117-biomedicines-08-00286">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernando</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H.P.V.</given-names>
</name>
<name>
<surname>Hoskin</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>Dietary phytochemicals with anti-oxidant and pro-oxidant activities: A double-edged sword in relation to adjuvant chemotherapy and radiotherapy?</article-title>
<source/>Cancer Lett.
          <year>2019</year>
<volume>452</volume>
<fpage>168</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2019.03.022</pub-id>
<pub-id pub-id-type="pmid">30910593</pub-id>
</element-citation>
</ref>
<ref id="B118-biomedicines-08-00286">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bobadilla</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>S.Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>High glucose-induced p53 phosphorylation contributes to impairment of endothelial antioxidant system</article-title>
<source/>Biochim. et Biophys. Acta (BBA) Mol. Basis Dis.
          <year>2017</year>
<volume>1863</volume>
<fpage>2355</fpage>
<lpage>2362</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2017.06.022</pub-id>
</element-citation>
</ref>
<ref id="B119-biomedicines-08-00286">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Angelo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martino</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ilisso</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Bagarolo</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Porcelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cacciapuoti</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Pro-oxidant and pro-apoptotic activity of polyphenol extract from Annurca apple and its underlying mechanisms in human breast cancer cells</article-title>
<source/>Int. J. Oncol.
          <year>2017</year>
<volume>51</volume>
<fpage>939</fpage>
<lpage>948</lpage>
<pub-id pub-id-type="doi">10.3892/ijo.2017.4088</pub-id>
<pub-id pub-id-type="pmid">28766690</pub-id>
</element-citation>
</ref>
<ref id="B120-biomedicines-08-00286">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sablina</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Budanov</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Ilyinskaya</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>Agapova</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Kravchenko</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Chumakov</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>The antioxidant function of the p53 tumor suppressor</article-title>
<source/>Nat. Med.
          <year>2005</year>
<volume>11</volume>
<fpage>1306</fpage>
<lpage>1313</lpage>
<pub-id pub-id-type="doi">10.1038/nm1320</pub-id>
<pub-id pub-id-type="pmid">16286925</pub-id>
</element-citation>
</ref>
<ref id="B121-biomedicines-08-00286">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vazhappilly</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Ansari</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Al-Jaleeli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Al-Azawi</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Ramadan</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hodeify</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Merheb</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Matar</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of flavonoids in thrombotic, cardiovascular, and inflammatory diseases</article-title>
<source/>Inflammopharmacol
          <year>2019</year>
<volume>27</volume>
<fpage>863</fpage>
<lpage>869</lpage>
<pub-id pub-id-type="doi">10.1007/s10787-019-00612-6</pub-id>
</element-citation>
</ref>
<ref id="B122-biomedicines-08-00286">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunathilake</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ranaweera</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>In Vitro Anti-Inflammatory Properties of Selected Green Leafy Vegetables</article-title>
<source/>Biomedicines
          <year>2018</year>
<volume>6</volume>
<elocation-id>107</elocation-id>
<pub-id pub-id-type="doi">10.3390/biomedicines6040107</pub-id>
<pub-id pub-id-type="pmid">30463216</pub-id>
</element-citation>
</ref>
<ref id="B123-biomedicines-08-00286">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Vijesh</surname>
<given-names>V.V.</given-names>
</name>
<name>
<surname>Amararathna</surname>
<given-names>D.I.M.</given-names>
</name>
<name>
<surname>Lakshmi</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Anbarasu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>D.R.N.</given-names>
</name>
<name>
<surname>Ethiraj</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H.P.V.</given-names>
</name>
</person-group>
<article-title>Mechanism of Action of Flavonoids in Prevention of Inflammation-Associated Skin Cancer</article-title>
<source/>CMC
          <year>2016</year>
<volume>23</volume>
<fpage>3697</fpage>
<lpage>3716</lpage>
<pub-id pub-id-type="doi">10.2174/0929867323666160627110342</pub-id>
<pub-id pub-id-type="pmid">27356537</pub-id>
</element-citation>
</ref>
<ref id="B124-biomedicines-08-00286">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spiegel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Andruniów</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sroka</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Flavones’ and Flavonols’ Antiradical Structure–Activity Relationship—A Quantum Chemical Study</article-title>
<source/>Antioxidants
          <year>2020</year>
<volume>9</volume>
<elocation-id>461</elocation-id>
<pub-id pub-id-type="doi">10.3390/antiox9060461</pub-id>
<pub-id pub-id-type="pmid">32471289</pub-id>
</element-citation>
</ref>
<ref id="B125-biomedicines-08-00286">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarian</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>Q.U.</given-names>
</name>
<name>
<surname>Mat So’ad</surname>
<given-names>S.Z.</given-names>
</name>
<name>
<surname>Alhassan</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Murugesu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Perumal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Syed Mohamad</surname>
<given-names>S.N.A.</given-names>
</name>
<name>
<surname>Khatib</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Latip</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Antioxidant and Antidiabetic Effects of Flavonoids: A Structure-Activity Relationship Based Study</article-title>
<source/>BioMed Res. Int.
          <year>2017</year>
<volume>2017</volume>
<fpage>8386065</fpage>
<pub-id pub-id-type="doi">10.1155/2017/8386065</pub-id>
<pub-id pub-id-type="pmid">29318154</pub-id>
</element-citation>
</ref>
<ref id="B126-biomedicines-08-00286">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sordon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Popłoński</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Milczarek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stachowicz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tronina</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kucharska</surname>
<given-names>A.Z.</given-names>
</name>
<name>
<surname>Wietrzyk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huszcza</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Structure–Antioxidant–Antiproliferative Activity Relationships of Natural C7 and C7–C8 Hydroxylated Flavones and Flavanones</article-title>
<source/>Antioxidants
          <year>2019</year>
<volume>8</volume>
<elocation-id>210</elocation-id>
<pub-id pub-id-type="doi">10.3390/antiox8070210</pub-id>
</element-citation>
</ref>
<ref id="B127-biomedicines-08-00286">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ashida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Terao</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Multitargeted cancer prevention by quercetin</article-title>
<source/>Cancer Lett.
          <year>2008</year>
<volume>269</volume>
<fpage>315</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2008.03.046</pub-id>
<pub-id pub-id-type="pmid">18467024</pub-id>
</element-citation>
</ref>
<ref id="B128-biomedicines-08-00286">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Quercetin protect cigarette smoke extracts induced inflammation and apoptosis in RPE cells</article-title>
<source/>Artif. Cells Nanomed. Biotechnol.
          <year>2019</year>
<volume>47</volume>
<fpage>2010</fpage>
<lpage>2015</lpage>
<pub-id pub-id-type="doi">10.1080/21691401.2019.1608217</pub-id>
<pub-id pub-id-type="pmid">31122072</pub-id>
</element-citation>
</ref>
<ref id="B129-biomedicines-08-00286">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisek</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Campaner</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ciani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Walerych</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Del Sal</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells</article-title>
<source/>Oncotarget
          <year>2018</year>
<volume>9</volume>
<fpage>20508</fpage>
<lpage>20523</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.24974</pub-id>
<pub-id pub-id-type="pmid">29755668</pub-id>
</element-citation>
</ref>
<ref id="B130-biomedicines-08-00286">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xv</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Berberine ameliorates CCl4-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways</article-title>
<source/>Mol. Med. Rep.
          <year>2019</year>
<volume>20</volume>
<fpage>3095</fpage>
<lpage>3102</lpage>
<pub-id pub-id-type="doi">10.3892/mmr.2019.10551</pub-id>
<pub-id pub-id-type="pmid">31432116</pub-id>
</element-citation>
</ref>
<ref id="B131-biomedicines-08-00286">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vinayak</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Long Term Effect of Curcumin in Restoration of Tumour Suppressor p53 and Phase-II Antioxidant Enzymes via Activation of Nrf2 Signalling and Modulation of Inflammation in Prevention of Cancer</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0124000</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0124000</pub-id>
<pub-id pub-id-type="pmid">25860911</pub-id>
</element-citation>
</ref>
<ref id="B132-biomedicines-08-00286">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>C.K.</given-names>
</name>
</person-group>
<article-title>Protective effect of flavonoid-rich extract from Rosa laevigata Michx on cerebral ischemia–reperfusion injury through suppression of apoptosis and inflammation</article-title>
<source/>Neurochem. Int.
          <year>2013</year>
<volume>63</volume>
<fpage>522</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2013.08.008</pub-id>
<pub-id pub-id-type="pmid">24012531</pub-id>
</element-citation>
</ref>
<ref id="B133-biomedicines-08-00286">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>O.M.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Fahim</surname>
<given-names>H.I.</given-names>
</name>
<name>
<surname>Zaky</surname>
<given-names>M.Y.</given-names>
</name>
</person-group>
<article-title>Quercetin and naringenin abate diethylnitrosamine/acetylaminofluorene-induced hepatocarcinogenesis in Wistar rats: The roles of oxidative stress, inflammation and cell apoptosis</article-title>
<source/>Drug Chem. Toxicol.
          <year>2019</year>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1080/01480545.2019.1683187</pub-id>
</element-citation>
</ref>
<ref id="B134-biomedicines-08-00286">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le</surname>
<given-names>N.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C.-S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.H.Y.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>M.-K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>S.-M.</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Goto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawada</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quercetin Protects against Obesity-Induced Skeletal Muscle Inflammation and Atrophy</article-title>
<source/>Mediat. Inflamm.
          <year>2014</year>
<volume>2014</volume>
<fpage>834294</fpage>
<pub-id pub-id-type="doi">10.1155/2014/834294</pub-id>
</element-citation>
</ref>
<ref id="B135-biomedicines-08-00286">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perdicaro</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Rodriguez Lanzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gambarte Tudela</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Miatello</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Oteiza</surname>
<given-names>P.I.</given-names>
</name>
<name>
<surname>Vazquez Prieto</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Quercetin attenuates adipose hypertrophy, in part through activation of adipogenesis in rats fed a high-fat diet</article-title>
<source/>J. Nutr. Biochem.
          <year>2020</year>
<volume>79</volume>
<fpage>108352</fpage>
<pub-id pub-id-type="doi">10.1016/j.jnutbio.2020.108352</pub-id>
<pub-id pub-id-type="pmid">32145471</pub-id>
</element-citation>
</ref>
<ref id="B136-biomedicines-08-00286">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Min</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ebeler</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Quercetin inhibits hydrogen peroxide-induced DNA damage and enhances DNA repair in Caco-2 cells</article-title>
<source/>Food Chem. Toxicol.
          <year>2009</year>
<volume>47</volume>
<fpage>2716</fpage>
<lpage>2722</lpage>
<pub-id pub-id-type="doi">10.1016/j.fct.2009.07.033</pub-id>
<pub-id pub-id-type="pmid">19651184</pub-id>
</element-citation>
</ref>
<ref id="B137-biomedicines-08-00286">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Quercetin attenuates high glucose-induced injury in human retinal pigment epithelial cell line ARPE-19 by up-regulation of miR-29b</article-title>
<source/>J. Biochem.
          <year>2020</year>
<volume>167</volume>
<fpage>495</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1093/jb/mvaa001</pub-id>
<pub-id pub-id-type="pmid">31960917</pub-id>
</element-citation>
</ref>
<ref id="B138-biomedicines-08-00286">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darband</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Sadighparvar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yousefi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kaviani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ghaderi-Pakdel</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mihanfar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rahimi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mobaraki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Majidinia</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Quercetin attenuated oxidative DNA damage through NRF2 signaling pathway in rats with DMH induced colon carcinogenesis</article-title>
<source/>Life Sci.
          <year>2020</year>
<volume>253</volume>
<fpage>117584</fpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2020.117584</pub-id>
<pub-id pub-id-type="pmid">32220623</pub-id>
</element-citation>
</ref>
<ref id="B139-biomedicines-08-00286">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clemente-Soto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salas-Vidal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Milan-Pacheco</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sánchez-Carranza</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peralta-Zaragoza</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>González-Maya</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression-independent manner in HPV-positive human cervical cancer-derived cells</article-title>
<source/>Mol. Med. Rep.
          <year>2019</year>
<volume>19</volume>
<fpage>2097</fpage>
<lpage>2106</lpage>
<pub-id pub-id-type="doi">10.3892/mmr.2019.9850</pub-id>
<pub-id pub-id-type="pmid">30664221</pub-id>
</element-citation>
</ref>
<ref id="B140-biomedicines-08-00286">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neuwirthová</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gál</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Smilek</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Urbánková</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Potential of the Flavonoid Quercetin to Prevent and Treat Cancer—Current Status of Research</article-title>
<source/>Klin. Onkol.
          <year>2018</year>
<volume>31</volume>
<fpage>184</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.14735/amko2018184</pub-id>
<pub-id pub-id-type="pmid">30441971</pub-id>
</element-citation>
</ref>
<ref id="B141-biomedicines-08-00286">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Luteolin reduces inflammation in <italic>Staphylococcus aureus</italic>-induced mastitis by inhibiting NF-κB activation and MMPs expression</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>28481</fpage>
<lpage>28493</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.16092</pub-id>
<pub-id pub-id-type="pmid">28415707</pub-id>
</element-citation>
</ref>
<ref id="B142-biomedicines-08-00286">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>AL-Megrin</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Alomar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alkhuriji</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Metwally</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Kassab</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Abdel Moneim</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>El-Khadragy</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Luteolin protects against testicular injury induced by lead acetate by activating the Nrf2/ <sc>HO</sc><sup>−1</sup> pathway</article-title>
<source/>IUBMB Life
          <year>2020</year>
<volume>72</volume>
<fpage>1787</fpage>
<lpage>1798</lpage>
<pub-id pub-id-type="doi">10.1002/iub.2311</pub-id>
<pub-id pub-id-type="pmid">32478470</pub-id>
</element-citation>
</ref>
<ref id="B143-biomedicines-08-00286">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H.-M.</given-names>
</name>
</person-group>
<article-title>Luteolin, a flavonoid with potential for cancer prevention and therapy</article-title>
<source/>Curr. Cancer Drug Targets
          <year>2008</year>
<volume>8</volume>
<fpage>634</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.2174/156800908786241050</pub-id>
<pub-id pub-id-type="pmid">18991571</pub-id>
</element-citation>
</ref>
<ref id="B144-biomedicines-08-00286">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shaukat</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Luteoloside Protects the Uterus from Staphylococcus aureus-Induced Inflammation, Apoptosis, and Injury</article-title>
<source/>Inflammation
          <year>2018</year>
<volume>41</volume>
<fpage>1702</fpage>
<lpage>1716</lpage>
<pub-id pub-id-type="doi">10.1007/s10753-018-0814-7</pub-id>
<pub-id pub-id-type="pmid">29987481</pub-id>
</element-citation>
</ref>
<ref id="B145-biomedicines-08-00286">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses</article-title>
<source/>Phytomedicine
          <year>2019</year>
<volume>59</volume>
<fpage>152774</fpage>
<pub-id pub-id-type="doi">10.1016/j.phymed.2018.11.034</pub-id>
<pub-id pub-id-type="pmid">31009852</pub-id>
</element-citation>
</ref>
<ref id="B146-biomedicines-08-00286">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amin</surname>
<given-names>A.R.M.R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>H.J.C.</given-names>
</name>
<name>
<surname>Brandes</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Tighiouart</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khuri</surname>
<given-names>F.R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.G.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Enhanced Anti-tumor Activity by the Combination of the Natural Compounds (−)-Epigallocatechin-3-gallate and Luteolin: Potential Role of p53</article-title>
<source/>J. Biol. Chem.
          <year>2010</year>
<volume>285</volume>
<fpage>34557</fpage>
<lpage>34565</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.141135</pub-id>
<pub-id pub-id-type="pmid">20826787</pub-id>
</element-citation>
</ref>
<ref id="B147-biomedicines-08-00286">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>C.-Q.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>T.-T.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>S.-C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.-Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.-M.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.-Y.</given-names>
</name>
</person-group>
<article-title>P53 and mitochondrial dysfunction: Novel insight of neurodegenerative diseases</article-title>
<source/>J. Bioenerg. Biomembr.
          <year>2016</year>
<volume>48</volume>
<fpage>337</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="doi">10.1007/s10863-016-9669-5</pub-id>
<pub-id pub-id-type="pmid">27422544</pub-id>
</element-citation>
</ref>
<ref id="B148-biomedicines-08-00286">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>Z.-Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.-H.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y.-M.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.-Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p</article-title>
<source/>Int. J. Mol. Sci.
          <year>2018</year>
<volume>19</volume>
<elocation-id>447</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms19020447</pub-id>
</element-citation>
</ref>
<ref id="B149-biomedicines-08-00286">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pérez-Sánchez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barrajón-Catalán</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Herranz-López</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Micol</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Lemon balm extract (Melissa officinalis, L.) promotes melanogenesis and prevents UVB-induced oxidative stress and DNA damage in a skin cell model</article-title>
<source/>J. Dermatol. Sci.
          <year>2016</year>
<volume>84</volume>
<fpage>169</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1016/j.jdermsci.2016.08.004</pub-id>
<pub-id pub-id-type="pmid">27528586</pub-id>
</element-citation>
</ref>
<ref id="B150-biomedicines-08-00286">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>D.R.N.</given-names>
</name>
<name>
<surname>Suresh</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Comparative Studies to Evaluate Relative in vitro Potency of Luteolin in Inducing Cell Cycle Arrest and Apoptosis in HaCaT and A375 Cells</article-title>
<source/>Asian Pac. J. Cancer Prev.
          <year>2013</year>
<volume>14</volume>
<fpage>631</fpage>
<lpage>637</lpage>
<pub-id pub-id-type="doi">10.7314/APJCP.2013.14.2.631</pub-id>
<pub-id pub-id-type="pmid">23621210</pub-id>
</element-citation>
</ref>
<ref id="B151-biomedicines-08-00286">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>T.-T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.-K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>G.-L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>G.-J.</given-names>
</name>
</person-group>
<article-title>Luteolin Induced-growth Inhibition and Apoptosis of Human Esophageal Squamous Carcinoma Cell Line Eca109 Cells in vitro</article-title>
<source/>Asian Pac. J. Cancer Prev.
          <year>2012</year>
<volume>13</volume>
<fpage>5455</fpage>
<lpage>5461</lpage>
<pub-id pub-id-type="doi">10.7314/APJCP.2012.13.11.5455</pub-id>
<pub-id pub-id-type="pmid">23317200</pub-id>
</element-citation>
</ref>
<ref id="B152-biomedicines-08-00286">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Protective effect of epigallocatechin-3-gallate against neuroinflammation and anxiety-like behavior in a rat model of myocardial infarction</article-title>
<source/>Brain Behav.
          <year>2020</year>
<volume>10</volume>
<fpage>e01633</fpage>
<pub-id pub-id-type="doi">10.1002/brb3.1633</pub-id>
<pub-id pub-id-type="pmid">32304289</pub-id>
</element-citation>
</ref>
<ref id="B153-biomedicines-08-00286">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.X.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>P.Y.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>S.O.</given-names>
</name>
</person-group>
<article-title>Green tea extract attenuates LPS-induced retinal inflammation in rats</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>429</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-18888-5</pub-id>
<pub-id pub-id-type="pmid">29323215</pub-id>
</element-citation>
</ref>
<ref id="B154-biomedicines-08-00286">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oblak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jerala</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Toll-Like Receptor 4 Activation in Cancer Progression and Therapy</article-title>
<source/>Clin. Dev. Immunol.
          <year>2011</year>
<volume>2011</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1155/2011/609579</pub-id>
<pub-id pub-id-type="pmid">22110526</pub-id>
</element-citation>
</ref>
<ref id="B155-biomedicines-08-00286">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>C.-L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.-M.</given-names>
</name>
</person-group>
<article-title>The Cancer Prevention, Anti-Inflammatory and Anti-Oxidation of Bioactive Phytochemicals Targeting the TLR4 Signaling Pathway</article-title>
<source/>Int. J. Mol. Sci.
          <year>2018</year>
<volume>19</volume>
<elocation-id>2729</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms19092729</pub-id>
<pub-id pub-id-type="pmid">30213077</pub-id>
</element-citation>
</ref>
<ref id="B156-biomedicines-08-00286">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Epigallocatechin-3-gallate alleviates paraquat-induced acute lung injury and inhibits upregulation of toll-like receptors</article-title>
<source/>Life Sci.
          <year>2017</year>
<volume>170</volume>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2016.11.021</pub-id>
<pub-id pub-id-type="pmid">27890776</pub-id>
</element-citation>
</ref>
<ref id="B157-biomedicines-08-00286">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Maghrebi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alnajem</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Esmaeil</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Epigallocatechin-3-gallate modulates germ cell apoptosis through the SAFE/Nrf2 signaling pathway</article-title>
<source/>Naunyn Schmiedeberg’s Arch. Pharmacol.
          <year>2020</year>
<volume>393</volume>
<fpage>663</fpage>
<lpage>671</lpage>
<pub-id pub-id-type="doi">10.1007/s00210-019-01776-2</pub-id>
<pub-id pub-id-type="pmid">31807839</pub-id>
</element-citation>
</ref>
<ref id="B158-biomedicines-08-00286">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Epigallocatechin-3-gallate attenuates acrylamide-induced apoptosis and astrogliosis in rat cerebral cortex</article-title>
<source/>Toxicol. Mech. Methods
          <year>2017</year>
<volume>27</volume>
<fpage>298</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="doi">10.1080/15376516.2017.1279251</pub-id>
<pub-id pub-id-type="pmid">28056603</pub-id>
</element-citation>
</ref>
<ref id="B159-biomedicines-08-00286">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Remely</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ferk</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sterneder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Setayesh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kepcija</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Noorizadeh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rebhan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Greunz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Beckmann</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>EGCG Prevents High Fat Diet-Induced Changes in Gut Microbiota, Decreases of DNA Strand Breaks, and Changes in Expression and DNA Methylation of <italic>Dnmt1</italic> and <italic>MLH1</italic> in C57BL/6J Male Mice</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2017</year>
<volume>2017</volume>
<fpage>3079148</fpage>
<pub-id pub-id-type="doi">10.1155/2017/3079148</pub-id>
<pub-id pub-id-type="pmid">28133504</pub-id>
</element-citation>
</ref>
<ref id="B160-biomedicines-08-00286">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Dellaire</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H.P.V.</given-names>
</name>
</person-group>
<article-title>Plant flavonoids in cancer chemoprevention: Role in genome stability</article-title>
<source/>J. Nutr. Biochem.
          <year>2017</year>
<volume>45</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1016/j.jnutbio.2016.11.007</pub-id>
<pub-id pub-id-type="pmid">27951449</pub-id>
</element-citation>
</ref>
<ref id="B161-biomedicines-08-00286">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Ansari</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Chelakkot</surname>
<given-names>V.S.</given-names>
</name>
<name>
<surname>Chelakkot</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Chelakkot</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ramadan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ethiraj</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>El-Awady</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mantso</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNA-dependent protein kinase: Epigenetic alterations and the role in genomic stability of cancer</article-title>
<source/>Mutat. Res. Rev. Mutat. Res.
          <year>2019</year>
<volume>780</volume>
<fpage>92</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.mrrev.2018.06.001</pub-id>
</element-citation>
</ref>
<ref id="B162-biomedicines-08-00286">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Silva</surname>
<given-names>A.B.K.H.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H.P.V.</given-names>
</name>
</person-group>
<article-title>Polyphenols composition and anti-diabetic properties in vitro of haskap (Lonicera caerulea L.) berries in relation to cultivar and harvesting date</article-title>
<source/>J. Food Compos. Anal.
          <year>2020</year>
<volume>88</volume>
<fpage>103402</fpage>
<pub-id pub-id-type="doi">10.1016/j.jfca.2019.103402</pub-id>
</element-citation>
</ref>
<ref id="B163-biomedicines-08-00286">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Cyanidin-3-<italic>O</italic>-Glucoside and Cyanidin Protect Against Intestinal Barrier Damage and 2,4,6-Trinitrobenzenesulfonic Acid-Induced Colitis</article-title>
<source/>J. Med. Food
          <year>2020</year>
<volume>23</volume>
<fpage>90</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1089/jmf.2019.4524</pub-id>
<pub-id pub-id-type="pmid">31657664</pub-id>
</element-citation>
</ref>
<ref id="B164-biomedicines-08-00286">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>H.X.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.S.</given-names>
</name>
</person-group>
<article-title>Cyanidin-3-glucoside from Black Rice Ameliorates Diabetic Nephropathy via Reducing Blood Glucose, Suppressing Oxidative Stress and Inflammation, and Regulating Transforming Growth Factor β1/Smad Expression</article-title>
<source/>J. Agric. Food Chem.
          <year>2020</year>
<volume>68</volume>
<fpage>4399</fpage>
<lpage>4410</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jafc.0c00680</pub-id>
<pub-id pub-id-type="pmid">32192334</pub-id>
</element-citation>
</ref>
<ref id="B165-biomedicines-08-00286">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nanoencapsulation of Cyanidin-3-<italic>O</italic>-glucoside Enhances Protection Against UVB-Induced Epidermal Damage through Regulation of p53-Mediated Apoptosis in Mice</article-title>
<source/>J. Agric. Food Chem.
          <year>2018</year>
<volume>66</volume>
<fpage>5359</fpage>
<lpage>5367</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jafc.8b01002</pub-id>
<pub-id pub-id-type="pmid">29732888</pub-id>
</element-citation>
</ref>
<ref id="B166-biomedicines-08-00286">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amararathna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hoskin</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H.P.V.</given-names>
</name>
</person-group>
<article-title>Anthocyanin-rich haskap (Lonicera caerulea L.) berry extracts reduce nitrosamine-induced DNA damage in human normal lung epithelial cells</article-title>
<source/>Food Chem. Toxicol.
          <year>2020</year>
<volume>141</volume>
<fpage>111404</fpage>
<pub-id pub-id-type="doi">10.1016/j.fct.2020.111404</pub-id>
<pub-id pub-id-type="pmid">32413456</pub-id>
</element-citation>
</ref>
<ref id="B167-biomedicines-08-00286">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protective Effect of Cyanidin-3-O-Glucoside against Ultraviolet B Radiation-Induced Cell Damage in Human HaCaT Keratinocytes</article-title>
<source/>Front. Pharmacol.
          <year>2016</year>
<volume>7</volume>
<fpage>301</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2016.00301</pub-id>
<pub-id pub-id-type="pmid">27656146</pub-id>
</element-citation>
</ref>
<ref id="B168-biomedicines-08-00286">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H.P.V.</given-names>
</name>
</person-group>
<article-title>Apple Flavonoids Suppress Carcinogen-Induced DNA Damage in Normal Human Bronchial Epithelial Cells</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2017</year>
<volume>2017</volume>
<fpage>1767198</fpage>
<pub-id pub-id-type="doi">10.1155/2017/1767198</pub-id>
<pub-id pub-id-type="pmid">28698766</pub-id>
</element-citation>
</ref>
<ref id="B169-biomedicines-08-00286">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaewmool</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Udomruk</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Phitak</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pothacharoen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kongtawelert</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Cyanidin-3-O-Glucoside Protects PC12 Cells Against Neuronal Apoptosis Mediated by LPS-Stimulated BV2 Microglial Activation</article-title>
<source/>Neurotox. Res.
          <year>2020</year>
<volume>37</volume>
<fpage>111</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-019-00102-1</pub-id>
<pub-id pub-id-type="pmid">31485933</pub-id>
</element-citation>
</ref>
<ref id="B170-biomedicines-08-00286">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Ameliorative Effect of Daidzein on Cisplatin-Induced Nephrotoxicity in Mice via Modulation of Inflammation, Oxidative Stress, and Cell Death</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2017</year>
<volume>2017</volume>
<fpage>3140680</fpage>
<pub-id pub-id-type="doi">10.1155/2017/3140680</pub-id>
<pub-id pub-id-type="pmid">28831294</pub-id>
</element-citation>
</ref>
<ref id="B171-biomedicines-08-00286">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Naka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ohara</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Daidzein regulates proinflammatory adipokines thereby improving obesity-related inflammation through PPARγ</article-title>
<source/>Mol. Nutr. Food Res.
          <year>2014</year>
<volume>58</volume>
<fpage>718</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1002/mnfr.201300482</pub-id>
<pub-id pub-id-type="pmid">24343975</pub-id>
</element-citation>
</ref>
<ref id="B172-biomedicines-08-00286">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Daidzein attenuates lipopolysaccharide-induced acute lung injury via toll-like receptor 4/NF-kappaB pathway</article-title>
<source/>Int. Immunopharmacol.
          <year>2015</year>
<volume>26</volume>
<fpage>392</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2015.04.002</pub-id>
<pub-id pub-id-type="pmid">25887269</pub-id>
</element-citation>
</ref>
<ref id="B173-biomedicines-08-00286">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iovine</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Iannella</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Gasparri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Monfrecola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bevilacqua</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Synergic Effect of Genistein and Daidzein on UVB-Induced DNA Damage: An Effective Photoprotective Combination</article-title>
<source/>J. Biomed. Biotechnol.
          <year>2011</year>
<volume>2011</volume>
<fpage>692846</fpage>
<pub-id pub-id-type="doi">10.1155/2011/692846</pub-id>
<pub-id pub-id-type="pmid">21785564</pub-id>
</element-citation>
</ref>
<ref id="B174-biomedicines-08-00286">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iovine</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Garofalo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Orefice</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giannini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gasparri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Monfrecola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bevilacqua</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Isoflavones in aglycone solution enhance ultraviolet B-induced DNA damage repair efficiency</article-title>
<source/>Clin. Exp. Dermatol.
          <year>2014</year>
<volume>39</volume>
<fpage>391</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1111/ced.12290</pub-id>
<pub-id pub-id-type="pmid">24635083</pub-id>
</element-citation>
</ref>
<ref id="B175-biomedicines-08-00286">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zare</surname>
<given-names>M.F.R.</given-names>
</name>
<name>
<surname>Rakhshan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aboutaleb</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nikbakht</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Naderi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bakhshesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Azizi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Apigenin attenuates doxorubicin induced cardiotoxicity via reducing oxidative stress and apoptosis in male rats</article-title>
<source/>Life Sci.
          <year>2019</year>
<volume>232</volume>
<fpage>116623</fpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2019.116623</pub-id>
<pub-id pub-id-type="pmid">31279781</pub-id>
</element-citation>
</ref>
<ref id="B176-biomedicines-08-00286">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Apigenin Alleviates Endotoxin-Induced Myocardial Toxicity by Modulating Inflammation, Oxidative Stress, and Autophagy</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2017</year>
<volume>2017</volume>
<fpage>2302896</fpage>
<pub-id pub-id-type="doi">10.1155/2017/2302896</pub-id>
<pub-id pub-id-type="pmid">28828145</pub-id>
</element-citation>
</ref>
<ref id="B177-biomedicines-08-00286">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirzoeva</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bridgeman</surname>
<given-names>B.B.</given-names>
</name>
<name>
<surname>Plebanek</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Volpert</surname>
<given-names>O.V.</given-names>
</name>
</person-group>
<article-title>Apigenin Inhibits UVB-Induced Skin Carcinogenesis: The Role of Thrombospondin-1 as an Anti-Inflammatory Factor</article-title>
<source/>Neoplasia
          <year>2018</year>
<volume>20</volume>
<fpage>930</fpage>
<lpage>942</lpage>
<pub-id pub-id-type="doi">10.1016/j.neo.2018.07.005</pub-id>
<pub-id pub-id-type="pmid">30118999</pub-id>
</element-citation>
</ref>
<ref id="B178-biomedicines-08-00286">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ai</surname>
<given-names>X.-Y.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Z.-H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>W.-L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.-R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-κB signaling</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>100216</fpage>
<lpage>100226</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.22145</pub-id>
<pub-id pub-id-type="pmid">29245972</pub-id>
</element-citation>
</ref>
<ref id="B179-biomedicines-08-00286">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thangaiyan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Arjunan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Govindasamy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nagarajan</surname>
<given-names>R.P.</given-names>
</name>
</person-group>
<article-title>Preventive effect of apigenin against isoproterenol-induced apoptosis in cardiomyoblasts</article-title>
<source/>J. Biochem. Mol. Toxicol.
          <year>2018</year>
<volume>32</volume>
<fpage>e22213</fpage>
<pub-id pub-id-type="doi">10.1002/jbt.22213</pub-id>
<pub-id pub-id-type="pmid">30152906</pub-id>
</element-citation>
</ref>
<ref id="B180-biomedicines-08-00286">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Farbood</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mansouri</surname>
<given-names>S.M.T.</given-names>
</name>
<name>
<surname>Badavi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khorsandi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dehcheshmeh</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Shooshtari</surname>
<given-names>M.K.</given-names>
</name>
</person-group>
<article-title>Chrysin prevents cognitive and hippocampal long-term potentiation deficits and inflammation in rat with cerebral hypoperfusion and reperfusion injury</article-title>
<source/>Life Sci.
          <year>2019</year>
<volume>226</volume>
<fpage>202</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2019.04.027</pub-id>
<pub-id pub-id-type="pmid">30991061</pub-id>
</element-citation>
</ref>
<ref id="B181-biomedicines-08-00286">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.-F.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.-W.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Y.-X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H.-F.</given-names>
</name>
<name>
<surname>Shui</surname>
<given-names>S.-F.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Chrysin ameliorates cerebral ischemia/reperfusion (I/R) injury in rats by regulating the PI3K/Akt/mTOR pathway</article-title>
<source/>Neurochem. Int.
          <year>2019</year>
<volume>129</volume>
<fpage>104496</fpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2019.104496</pub-id>
<pub-id pub-id-type="pmid">31247243</pub-id>
</element-citation>
</ref>
<ref id="B182-biomedicines-08-00286">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Fabbro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jesse</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>De Gomes</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Borges Filho</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Donato</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Goes</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Furian</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Boeira</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>The flavonoid chrysin protects against zearalenone induced reproductive toxicity in male mice</article-title>
<source/>Toxicon
          <year>2019</year>
<volume>165</volume>
<fpage>13</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.toxicon.2019.04.004</pub-id>
<pub-id pub-id-type="pmid">31004610</pub-id>
</element-citation>
</ref>
<ref id="B183-biomedicines-08-00286">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Marasy</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>El Awdan</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Abd-Elsalam</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Protective role of chrysin on thioacetamide-induced hepatic encephalopathy in rats</article-title>
<source/>Chem. Biol. Interact.
          <year>2019</year>
<volume>299</volume>
<fpage>111</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1016/j.cbi.2018.11.021</pub-id>
<pub-id pub-id-type="pmid">30500344</pub-id>
</element-citation>
</ref>
<ref id="B184-biomedicines-08-00286">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takaoka</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Okimura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kataoka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Koshiba</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kusuki</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Shigehiro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amami</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Daidzein-rich isoflavone aglycones inhibit cell growth and inflammation in endometriosis</article-title>
<source/>J. Steroid Biochem. Mol. Biol.
          <year>2018</year>
<volume>181</volume>
<fpage>125</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsbmb.2018.04.004</pub-id>
<pub-id pub-id-type="pmid">29679753</pub-id>
</element-citation>
</ref>
<ref id="B185-biomedicines-08-00286">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atiq</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shal</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Naveed</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeeshan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Al-Sharari</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Diadzein ameliorates 5-fluorouracil-induced intestinal mucositis by suppressing oxidative stress and inflammatory mediators in rodents</article-title>
<source/>Eur. J. Pharmacol.
          <year>2019</year>
<volume>843</volume>
<fpage>292</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2018.12.014</pub-id>
<pub-id pub-id-type="pmid">30529194</pub-id>
</element-citation>
</ref>
<ref id="B186-biomedicines-08-00286">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Oomagari</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tsuruta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shida</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kurokawa</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Citrus flavonoid naringenin inhibits TLR2 expression in adipocytes</article-title>
<source/>J. Nutr. Biochem.
          <year>2013</year>
<volume>24</volume>
<fpage>1276</fpage>
<lpage>1284</lpage>
<pub-id pub-id-type="doi">10.1016/j.jnutbio.2012.10.003</pub-id>
<pub-id pub-id-type="pmid">23333096</pub-id>
</element-citation>
</ref>
<ref id="B187-biomedicines-08-00286">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation</article-title>
<source/>Breast Cancer Res.
          <year>2016</year>
<volume>18</volume>
<fpage>38</fpage>
<pub-id pub-id-type="doi">10.1186/s13058-016-0698-0</pub-id>
<pub-id pub-id-type="pmid">27036297</pub-id>
</element-citation>
</ref>
<ref id="B188-biomedicines-08-00286">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chtourou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Slima</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Makni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gdoura</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fetoui</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Naringenin protects cardiac hypercholesterolemia-induced oxidative stress and subsequent necroptosis in rats</article-title>
<source/>Pharmacol. Rep.
          <year>2015</year>
<volume>67</volume>
<fpage>1090</fpage>
<lpage>1097</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharep.2015.04.002</pub-id>
<pub-id pub-id-type="pmid">26481526</pub-id>
</element-citation>
</ref>
<ref id="B189-biomedicines-08-00286">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>M.-S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Tsou</surname>
<given-names>H.-K.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>G.-G.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.-H.</given-names>
</name>
</person-group>
<article-title>Kaempferol protects against propacetamol-induced acute liver injury through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress, inflammation and apoptosis in mice</article-title>
<source/>Toxicol. Lett.
          <year>2018</year>
<volume>290</volume>
<fpage>97</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1016/j.toxlet.2018.03.024</pub-id>
<pub-id pub-id-type="pmid">29574133</pub-id>
</element-citation>
</ref>
<ref id="B190-biomedicines-08-00286">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kluska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Juszczak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wysokiński</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Żuchowski</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stochmal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Woźniak</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Kaempferol derivatives isolated from Lens culinaris Medik. reduce DNA damage induced by etoposide in peripheral blood mononuclear cells</article-title>
<source/>Toxicol. Res.
          <year>2019</year>
<volume>8</volume>
<fpage>896</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="doi">10.1039/c9tx00176j</pub-id>
</element-citation>
</ref>
<ref id="B191-biomedicines-08-00286">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pathak</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Biswas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mukhopadhyay</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>STAT3 and NF-κB are common targets for kaempferol-mediated attenuation of COX-2 expression in IL-6-induced macrophages and carrageenan-induced mouse paw edema</article-title>
<source/>Biochem. Biophys. Rep.
          <year>2017</year>
<volume>12</volume>
<fpage>54</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrep.2017.08.005</pub-id>
<pub-id pub-id-type="pmid">28955792</pub-id>
</element-citation>
</ref>
<ref id="B192-biomedicines-08-00286">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ansó</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zuazo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Irigoyen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Urdaci</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Rouzaut</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martínez-Irujo</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism</article-title>
<source/>Biochem. Pharmacol.
          <year>2010</year>
<volume>79</volume>
<fpage>1600</fpage>
<lpage>1609</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2010.02.004</pub-id>
<pub-id pub-id-type="pmid">20153296</pub-id>
</element-citation>
</ref>
<ref id="B193-biomedicines-08-00286">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seo</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>G.-S.</given-names>
</name>
</person-group>
<article-title>Fisetin inhibits TNF-α-induced inflammatory action and hydrogen peroxide-induced oxidative damage in human keratinocyte HaCaT cells through PI3K/AKT/Nrf-2-mediated heme oxygenase-1 expression</article-title>
<source/>Int. Immunopharmacol.
          <year>2015</year>
<volume>29</volume>
<fpage>246</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2015.11.014</pub-id>
<pub-id pub-id-type="pmid">26590114</pub-id>
</element-citation>
</ref>
<ref id="B194-biomedicines-08-00286">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Althunibat</surname>
<given-names>O.Y.</given-names>
</name>
<name>
<surname>Al Hroob</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Abukhalil</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Germoush</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Bin-Jumah</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mahmoud</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Fisetin ameliorates oxidative stress, inflammation and apoptosis in diabetic cardiomyopathy</article-title>
<source/>Life Sci.
          <year>2019</year>
<volume>221</volume>
<fpage>83</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2019.02.017</pub-id>
<pub-id pub-id-type="pmid">30742869</pub-id>
</element-citation>
</ref>
<ref id="B195-biomedicines-08-00286">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Myricetin attenuates LPS-induced inflammation in RAW 264.7 macrophages and mouse models</article-title>
<source/>Future Med. Chem.
          <year>2018</year>
<volume>10</volume>
<fpage>2253</fpage>
<lpage>2264</lpage>
<pub-id pub-id-type="doi">10.4155/fmc-2018-0172</pub-id>
<pub-id pub-id-type="pmid">30095283</pub-id>
</element-citation>
</ref>
<ref id="B196-biomedicines-08-00286">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M.-J.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>L.-G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>W.-S.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>X.-J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemopreventive effect of Myricetin, a natural occurring compound, on colonic chronic inflammation and inflammation-driven tumorigenesis in mice</article-title>
<source/>Biomed. Pharmacother.
          <year>2018</year>
<volume>97</volume>
<fpage>1131</fpage>
<lpage>1137</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2017.11.018</pub-id>
<pub-id pub-id-type="pmid">29136951</pub-id>
</element-citation>
</ref>
<ref id="B197-biomedicines-08-00286">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.-F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.-D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.-N.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.-Y.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>F.-T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hesperetin derivative attenuates CCl4-induced hepatic fibrosis and inflammation by Gli-1-dependent mechanisms</article-title>
<source/>Int. Immunopharmacol.
          <year>2019</year>
<volume>76</volume>
<fpage>105838</fpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2019.105838</pub-id>
<pub-id pub-id-type="pmid">31473406</pub-id>
</element-citation>
</ref>
<ref id="B198-biomedicines-08-00286">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samie</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sedaghat</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Baluchnejadmojarad</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Roghani</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Hesperetin, a citrus flavonoid, attenuates testicular damage in diabetic rats via inhibition of oxidative stress, inflammation, and apoptosis</article-title>
<source/>Life Sci.
          <year>2018</year>
<volume>210</volume>
<fpage>132</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2018.08.074</pub-id>
<pub-id pub-id-type="pmid">30179627</pub-id>
</element-citation>
</ref>
<ref id="B199-biomedicines-08-00286">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>A.-W.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>C.-M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Catechin attenuates TNF-α induced inflammatory response via AMPK-SIRT1 pathway in 3T3-L1 adipocytes</article-title>
<source/>PLoS ONE
          <year>2019</year>
<volume>14</volume>
<elocation-id>e0217090</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0217090</pub-id>
<pub-id pub-id-type="pmid">31100089</pub-id>
</element-citation>
</ref>
<ref id="B200-biomedicines-08-00286">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Al Maruf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>(+)-Catechin prevents methylglyoxal-induced mitochondrial dysfunction and apoptosis in EA.hy926 cells</article-title>
<source/>Arch. Physiol. Biochem.
          <year>2017</year>
<volume>123</volume>
<fpage>121</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1080/13813455.2016.1263868</pub-id>
<pub-id pub-id-type="pmid">28005432</pub-id>
</element-citation>
</ref>
<ref id="B201-biomedicines-08-00286">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knaze</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zamora-Ros</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Luján-Barroso</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Romieu</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Scalbert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Slimani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Riboli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Van Rossum</surname>
<given-names>C.T.M.</given-names>
</name>
<name>
<surname>Bueno-de-Mesquita</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Trichopoulou</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intake estimation of total and individual flavan-3-ols, proanthocyanidins and theaflavins, their food sources and determinants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study</article-title>
<source/>Br. J. Nutr.
          <year>2012</year>
<volume>108</volume>
<fpage>1095</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="doi">10.1017/S0007114511006386</pub-id>
<pub-id pub-id-type="pmid">22186699</pub-id>
</element-citation>
</ref>
<ref id="B202-biomedicines-08-00286">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Márquez Campos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jakobs</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>M.-C.</given-names>
</name>
</person-group>
<article-title>Antidiabetic Effects of Flavan-3-ols and Their Microbial Metabolites</article-title>
<source/>Nutrients
          <year>2020</year>
<volume>12</volume>
<elocation-id>1592</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu12061592</pub-id>
<pub-id pub-id-type="pmid">32485837</pub-id>
</element-citation>
</ref>
<ref id="B203-biomedicines-08-00286">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thilakarathna</surname>
<given-names>W.P.D.W.</given-names>
</name>
<name>
<surname>Rupasinghe</surname>
<given-names>H.P.V.</given-names>
</name>
</person-group>
<article-title>Microbial metabolites of proanthocyanidins reduce chemical carcinogen-induced DNA damage in human lung epithelial and fetal hepatic cells in vitro</article-title>
<source/>Food Chem. Toxicol.
          <year>2019</year>
<volume>125</volume>
<fpage>479</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="doi">10.1016/j.fct.2019.02.010</pub-id>
<pub-id pub-id-type="pmid">30735747</pub-id>
</element-citation>
</ref>
<ref id="B204-biomedicines-08-00286">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Flavan-3-ols consumption and cancer risk: A meta-analysis of epidemiologic studies</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>73573</fpage>
<lpage>73592</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.12017</pub-id>
<pub-id pub-id-type="pmid">27634884</pub-id>
</element-citation>
</ref>
<ref id="B205-biomedicines-08-00286">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gujar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wairkar</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Nanocrystal technology for improving therapeutic efficacy of flavonoids</article-title>
<source/>Phytomedicine
          <year>2020</year>
<volume>71</volume>
<fpage>153240</fpage>
<pub-id pub-id-type="doi">10.1016/j.phymed.2020.153240</pub-id>
<pub-id pub-id-type="pmid">32450461</pub-id>
</element-citation>
</ref>
<ref id="B206-biomedicines-08-00286">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassidy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bertoia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chiuve</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Forman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rimm</surname>
<given-names>E.B.</given-names>
</name>
</person-group>
<article-title>Habitual intake of anthocyanins and flavanones and risk of cardiovascular disease in men</article-title>
<source/>Am. J. Clin. Nutr.
          <year>2016</year>
<volume>104</volume>
<fpage>587</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="doi">10.3945/ajcn.116.133132</pub-id>
<pub-id pub-id-type="pmid">27488237</pub-id>
</element-citation>
</ref>
<ref id="B207-biomedicines-08-00286">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Anthocyanin Supplementation Improves HDL-Associated Paraoxonase 1 Activity and Enhances Cholesterol Efflux Capacity in Subjects With Hypercholesterolemia</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2014</year>
<volume>99</volume>
<fpage>561</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2013-2845</pub-id>
<pub-id pub-id-type="pmid">24285687</pub-id>
</element-citation>
</ref>
<ref id="B208-biomedicines-08-00286">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-inflammatory effect of purified dietary anthocyanin in adults with hypercholesterolemia: A randomized controlled trial</article-title>
<source/>Nutr. Metab. Cardiovasc. Dis.
          <year>2013</year>
<volume>23</volume>
<fpage>843</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="doi">10.1016/j.numecd.2012.06.005</pub-id>
<pub-id pub-id-type="pmid">22906565</pub-id>
</element-citation>
</ref>
<ref id="B209-biomedicines-08-00286">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barchitta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maugeri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>La Mastra</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>M.C.L.</given-names>
</name>
<name>
<surname>Favara</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lio</surname>
<given-names>R.M.S.</given-names>
</name>
<name>
<surname>Agodi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Dietary Antioxidant Intake and Human Papillomavirus Infection: Evidence from a Cross-Sectional Study in Italy</article-title>
<source/>Nutrients
          <year>2020</year>
<volume>12</volume>
<elocation-id>1384</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu12051384</pub-id>
</element-citation>
</ref>
<ref id="B210-biomedicines-08-00286">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Ferrars</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Czank</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Botting</surname>
<given-names>N.P.</given-names>
</name>
<name>
<surname>Kroon</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Cassidy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kay</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>The pharmacokinetics of anthocyanins and their metabolites in humans: Pharmacokinetics of a (13)C-labelled anthocyanin</article-title>
<source/>Br. J. Pharmacol.
          <year>2014</year>
<volume>171</volume>
<fpage>3268</fpage>
<lpage>3282</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12676</pub-id>
<pub-id pub-id-type="pmid">24602005</pub-id>
</element-citation>
</ref>
<ref id="B211-biomedicines-08-00286">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sudhakaran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Doseff</surname>
<given-names>A.I.</given-names>
</name>
</person-group>
<article-title>The Targeted Impact of Flavones on Obesity-Induced Inflammation and the Potential Synergistic Role in Cancer and the Gut Microbiota</article-title>
<source/>Molecules
          <year>2020</year>
<volume>25</volume>
<elocation-id>2477</elocation-id>
<pub-id pub-id-type="doi">10.3390/molecules25112477</pub-id>
</element-citation>
</ref>
<ref id="B212-biomedicines-08-00286">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Flavonoids from Mulberry Leaves Alleviate Lipid Dysmetabolism in High Fat Diet-Fed Mice: Involvement of Gut Microbiota</article-title>
<source/>Microorganisms
          <year>2020</year>
<volume>8</volume>
<elocation-id>860</elocation-id>
<pub-id pub-id-type="doi">10.3390/microorganisms8060860</pub-id>
<pub-id pub-id-type="pmid">32517288</pub-id>
</element-citation>
</ref>
<ref id="B213-biomedicines-08-00286">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamalifard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abbasalizadeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mirghafourvand</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bastani</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gholizadeh Shamasbi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khodaei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gholizadeh</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The effect of <italic>Seidlitzia rosmarinus</italic> (<italic>eshnan</italic>) on the prevention of recurrent cystitis in women of reproductive age: A randomized, controlled, clinical trial</article-title>
<source/>Phytother. Res.
          <year>2020</year>
<volume>34</volume>
<fpage>418</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1002/ptr.6534</pub-id>
<pub-id pub-id-type="pmid">31680378</pub-id>
</element-citation>
</ref>
<ref id="B214-biomedicines-08-00286">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pintova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dharmupari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moshier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zubizarreta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Holcombe</surname>
<given-names>R.F.</given-names>
</name>
</person-group>
<article-title>Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: Phase I/II pilot study</article-title>
<source/>Cancer Chemother. Pharmacol.
          <year>2019</year>
<volume>84</volume>
<fpage>591</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="doi">10.1007/s00280-019-03886-3</pub-id>
<pub-id pub-id-type="pmid">31203390</pub-id>
</element-citation>
</ref>
<ref id="B215-biomedicines-08-00286">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curtis</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Van der Velpen</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Berends</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jennings</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Feelisch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Umpleby</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>B.O.</given-names>
</name>
<name>
<surname>Meiss</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Minnion</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome—Results from a 6-month, double-blind, randomized controlled trial</article-title>
<source/>Am. J. Clin. Nutr.
          <year>2019</year>
<volume>109</volume>
<fpage>1535</fpage>
<lpage>1545</lpage>
<pub-id pub-id-type="doi">10.1093/ajcn/nqy380</pub-id>
<pub-id pub-id-type="pmid">31136659</pub-id>
</element-citation>
</ref>
<ref id="B216-biomedicines-08-00286">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakuradze</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tausend</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Galan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Groh</surname>
<given-names>I.A.M.</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tur</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Marko</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Richling</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Antioxidative activity and health benefits of anthocyanin-rich fruit juice in healthy volunteers</article-title>
<source/>Free Radic. Res.
          <year>2019</year>
<volume>53</volume>
<fpage>1045</fpage>
<lpage>1055</lpage>
<pub-id pub-id-type="doi">10.1080/10715762.2019.1618851</pub-id>
</element-citation>
</ref>
<ref id="B217-biomedicines-08-00286">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munguia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rubio-Gayosso</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ramirez-Sanchez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hidalgo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meaney</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Villarreal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Najera</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ceballos</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>High Flavonoid Cocoa Supplement Ameliorates Plasma Oxidative Stress and Inflammation Levels While Improving Mobility and Quality of Life in Older Subjects: A Double-Blind Randomized Clinical Trial</article-title>
<source/>J. Gerontol. Ser. A
          <year>2019</year>
<volume>74</volume>
<fpage>1620</fpage>
<lpage>1627</lpage>
<pub-id pub-id-type="doi">10.1093/gerona/glz107</pub-id>
</element-citation>
</ref>
<ref id="B218-biomedicines-08-00286">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pattanayak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Catalona</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genistein treatment duration effects biomarkers of cell motility in human prostate</article-title>
<source/>PLoS ONE
          <year>2019</year>
<volume>14</volume>
<elocation-id>e0214078</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0214078</pub-id>
<pub-id pub-id-type="pmid">30917169</pub-id>
</element-citation>
</ref>
<ref id="B219-biomedicines-08-00286">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>A prospective, three-arm, randomized trial of EGCG for preventing radiation-induced esophagitis in lung cancer patients receiving radiotherapy</article-title>
<source/>Radiother. Oncol.
          <year>2019</year>
<volume>137</volume>
<fpage>186</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2019.02.022</pub-id>
<pub-id pub-id-type="pmid">30898322</pub-id>
</element-citation>
</ref>
<ref id="B220-biomedicines-08-00286">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ud-Din</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Foden</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mazhari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Al-Habba</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Baguneid</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bulfone-Paus</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McGeorge</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bayat</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human Skin</article-title>
<source/>J. Investig. Dermatol.
          <year>2019</year>
<volume>139</volume>
<fpage>1680</fpage>
<lpage>1690</lpage>
<pub-id pub-id-type="doi">10.1016/j.jid.2019.01.030</pub-id>
<pub-id pub-id-type="pmid">30822414</pub-id>
</element-citation>
</ref>
<ref id="B221-biomedicines-08-00286">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazzucchi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Patrizio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ceci</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Duranti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sgrò</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Di Luigi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sacchetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Felici</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>The Effects of Quercetin Supplementation on Eccentric Exercise-Induced Muscle Damage</article-title>
<source/>Nutrients
          <year>2019</year>
<volume>11</volume>
<elocation-id>205</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu11010205</pub-id>
</element-citation>
</ref>
<ref id="B222-biomedicines-08-00286">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karbasforooshan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hosseini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Elyasi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fani Pakdel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Karimi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, double-blind, placebo-controlled clinical trial: Topical silymarin for prevention of radiodermatitis in breast cancer</article-title>
<source/>Phytother. Res.
          <year>2019</year>
<volume>33</volume>
<fpage>379</fpage>
<lpage>386</lpage>
<pub-id pub-id-type="doi">10.1002/ptr.6231</pub-id>
<pub-id pub-id-type="pmid">30479044</pub-id>
</element-citation>
</ref>
<ref id="B223-biomedicines-08-00286">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Pandita</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Eskiocak</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Ly</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kaisani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cornelius</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Pandita</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Shay</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2012</year>
<volume>109</volume>
<fpage>E2949</fpage>
<lpage>E2955</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1207718109</pub-id>
<pub-id pub-id-type="pmid">23045680</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="biomedicines-08-00286-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Infiltration of immune cells due to activation of p53: The activation of p53 in cancer cells can be due to many factors such as TLR5-flagellin interaction. Due to this activation of p53, the inflammatory mediators are released, which leads to the infiltration of immune cells in the tumor microenvironment. These immune cells include neutrophils, macrophages, and T cells.</p>
</caption>
<graphic xlink:href="biomedicines-08-00286-g001"></graphic>
</fig>
<fig id="biomedicines-08-00286-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Chronic inflammation-induced carcinogenesis: The process of carcinogenesis sometimes involves chronic inflammation induced by chemical carcinogens, reactive oxygen and nitrogen species, viruses, and bacteria. All these agents trigger mutation in the <italic>p53</italic> gene that ultimately leads to the transformation of normal cells into cancer cells.</p>
</caption>
<graphic xlink:href="biomedicines-08-00286-g002"></graphic>
</fig>
<fig id="biomedicines-08-00286-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Basic structure of a flavonoid and its subclasses.</p>
</caption>
<graphic xlink:href="biomedicines-08-00286-g003"></graphic>
</fig>
<fig id="biomedicines-08-00286-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Flavonoids inhibiting inflammatory and cancer markers: The flavonoids can modulate several receptors and their corresponding signaling cascades. The flavonoids exert its effects mainly through JAK/STAT, IKK/NF-κB, and MAPK pathways leading to inhibition of pro-inflammatory, pro-apoptotic, and pro-necroptosis markers. The effector molecules that are downregulated include cytokines and cell death markers such as IL-1β, TNF-α, IL-6, IL-8, caspase-3, etc. These cellular events ultimately lead to immune regulation and cancer prevention.</p>
</caption>
<graphic xlink:href="biomedicines-08-00286-g004"></graphic>
</fig>
<table-wrap id="biomedicines-08-00286-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">biomedicines-08-00286-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Flavonoids in preventing inflammation and cancer in preclinical and experimental cell models.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Flavonoid</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Disease/Oxidative Stress Imposed</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Preclinical or Cell Model</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Molecular Signaling/Pathway</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Inflammation/Cancer Prevention Status</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Apigenin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cardiotoxicity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreases caspase-3 and Bax</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibition of apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B175-biomedicines-08-00286">175</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Myocardial injury</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits TNF-α, IL-1β, MIP-1α, MIP-2, and NFκB</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B176-biomedicines-08-00286">176</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">UVB-induced skin cancer</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits IL-6 and IL-12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B177-biomedicines-08-00286">177</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Bowel disease and colitis-associated cancer</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice and HCT-116</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits STAT3 and NF-κB</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation-induced carcinogenesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B178-biomedicines-08-00286">178</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Isoproterenol hydrochloride-induced apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">H9C2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits Bax, caspase-3, -8, and -9 and cytochrome c</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cancer prevention</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B179-biomedicines-08-00286">179</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Chrysin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cerebral ischemia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits IL-1β and TNF-α</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B180-biomedicines-08-00286">180</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cerebral ischemia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits TNF-α, IL-6, and IL-1β; activates PI3K/Akt/mTOR pathway</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation and apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B181-biomedicines-08-00286">181</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reproductive toxicity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits IL-1β, TNF-α, IL-6, and IL-10; activates caspase 3 and 9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B182-biomedicines-08-00286">182</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hepatic encephalopathy</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increases glutathione level; inhibit NF-κB, TNF-α, IL-6, and TLR-4; reduces caspase-3 and hepatic necrosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation and apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B183-biomedicines-08-00286">183</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Daidzein</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Endometriosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">OESCs and NESCs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibited IL-6, IL-8, COX-2, TNF-α-induced IκB phosphorylation and p65</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B184-biomedicines-08-00286">184</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intestinal mucositis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits TNF-α, IL-1β, and IL-6; increases CAT and GPx level</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B185-biomedicines-08-00286">185</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Naringenin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Obesity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits TLRs and TNF-α</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B186-biomedicines-08-00286">186</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pulmonary metastasis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits Tgf-β1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cancer prevention</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B187-biomedicines-08-00286">187</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cardiac hypercholesterolemia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits DNA damage, TNF-α, and RIP3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits necroptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B188-biomedicines-08-00286">188</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Kaempferol</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Propacetamol-induced acute liver injury</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits cytochrome P450 2E1; restores SOD, GPx and CAT; inhibits Bax/Bcl-2 ratio</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Prevents apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B189-biomedicines-08-00286">189</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Etoposide-induced oxidative stress</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HL-60 and PBMCs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits DNA damage (tail length)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Prevents DNA damage</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B190-biomedicines-08-00286">190</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Paw Edema</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice and THP-1 (together)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits Cox-2; STAT3 and NF-κB</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B191-biomedicines-08-00286">191</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Brain Injury and neuroinflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits STAT3 and NF-κB p65</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B189-biomedicines-08-00286">189</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Fisetin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hypoxia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">NCI-H157</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit HIF 1-α and STAT3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Prevents hypoxia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B192-biomedicines-08-00286">192</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hydrogen peroxide-induced oxidative stress</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HaCaT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits iNOS, Cox-2, IL-1β, IL-6, and TNF-α</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B193-biomedicines-08-00286">193</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Diabetic cardiomyopathy</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Restores SOD and CAT; inhibits IL-1β, IL-6, and TNF-α; inhibits caspase-3, Bax, and Bax/Bcl-2 ratio</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation and apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B194-biomedicines-08-00286">194</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Myricetin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LPS-induced Inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice and RAW 264.7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits NF-κB p65 and AKT activation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B195-biomedicines-08-00286">195</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Colonic chronic-induced inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits TNF-α, IL-1β, IL-6, NF-κB, p-NF-κB, cyclooxygenase-2 (COX-2), PCNA, and Cyclin D1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits inflammation and tumor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B196-biomedicines-08-00286">196</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Hesperetin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hepatic fibrosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice and HSCs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit α-SMA, Col1α1, Col3α1 and TIMP-1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits inflammation and induce apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B197-biomedicines-08-00286">197</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Testicular Damage</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits malondialdehyde, ROS, DNA fragmentation, and caspase 3; inhibits TNFα and IL-17</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits inflammation and apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B198-biomedicines-08-00286">198</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Catechin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TNF-α-induced inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3T3-L1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibit IL-1α, IL-1β, IL-6, IL-12, p35, iNOS, Cox-2, NF-κB, AMPK, FOXO3a, and SIRT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B199-biomedicines-08-00286">199</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Methylglyoxal-induced cytotoxicity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EA.hy926</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits MMP and cytotoxicity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhibits apoptosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B200-biomedicines-08-00286">200</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="biomedicines-08-00286-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">biomedicines-08-00286-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Flavonoids-rich diet in disease prevention: a summary from recent (2019–2020) clinical trials.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Dietary Flavonoids</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Condition Studied</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Sample Details</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Key Observations</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>Seidlitzia Rosmarinus</italic> (flavonoid-rich)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Recurrent cystitis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">126 women</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lowered symptoms of cystitis; prevent the incidence of recurrent cystitis with no side effects</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B213-biomedicines-08-00286">213</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Genistein with FOLFOX</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Metastatic colorectal cancer</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13 patients</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Exposure of genistein with FOLFOX was safe and tolerable</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B214-biomedicines-08-00286">214</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Anthocyanin-rich blueberry</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Type 2 diabetes and CVD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">115 people</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Improved endothelial function, systemic arterial stiffness and attenuated cyclic guanosine monophosphate concentrations</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B215-biomedicines-08-00286">215</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Anthocyanin-rich fruit juice</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Healthy volunteers</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">57 males</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Demonstrated DNA-protective and anti-oxidant effects; reduction in body fat and an increase in fat-free mass with increased SOD level</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B216-biomedicines-08-00286">216</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Flavonoid-rich natural cocoa beverage</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Plasma oxidative stress and inflammation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">134 people</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Improved glycemia, triglyceridemia, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceridemia/HDL index, and oxidative markers</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B217-biomedicines-08-00286">217</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Genistein</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human prostate cancer</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14 males</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased Brain Abundant Membrane Attached Signal Protein 1(BASP1) expression; decreases MMP-2 in prostate tissue</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B218-biomedicines-08-00286">218</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EGCG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Acute radiation-induced esophagitis (ARIE)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">83 patients</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lowered ARIE by reducing acute pain index (API) and acute dysphagia index (ADI) without side effects</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B219-biomedicines-08-00286">219</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EGCG</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cutaneous scarring</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">62 humans</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced mast cells; down-regulated Vascular Endothelial Growth Factor A (VEGFA) and CD31; reduced scar thickness</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B220-biomedicines-08-00286">220</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Quercetin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Eccentric exercise-induced muscle damage</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12 males</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased the isometric strength for contraction; lower torque and muscle fiber conduction velocity; attenuate the severity of muscle weakness</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B221-biomedicines-08-00286">221</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Silymarin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Radiation-induced dermatitis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">40 patients</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Delayed in radiodermatitis development and progression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B222-biomedicines-08-00286">222</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>